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1. INTRODUCTION 
 
1.1. Secondary metabolites 
  
Formerly, secondary metabolites were defined as substances with a low molecular weight, 
which were not products of the primary metabolic pathway of the producing organism. As 
a matter of fact, it was thought that these products did not have a roll in the microbial 
primary functions or growth [1, 2]. Therefore, it was thought that production of secondary 
metabolites did not represent any advantage for the producing microorganism. Contrary, 
nowadays it is considered that cell investment in secondary metabolite production is almost 
the confirmation of a function that should give the organisms certain advantage against 
other members of the microbial community [3]. In fact, secondary metabolites are accepted 
to be essential for the producing cell as inhibitors of other organisms that compete for the 
same food supply or as regulators of cellular differentiation processes. In addition, it is 
reported that they are indeed products of biosynthetic pathways, which have evolved to 
give these types of advantages [4, 5].  
The nature has provided a broad spectrum of structurally diverse secondary metabolites [6-
8]. Despite this great diversity, microbial secondary metabolites are synthesised from only 
a few precursors, in pathways with a relative small number of reactions, which branch 
from just a limited number of reactions of the primary metabolism [5]. The mentioned 
structure diversity is reflected in a variety of biological activities as, for instance, inhibitors 
of enzymes and antitumor, immunosuppressive and antiparasitic agents [4, 9]. Aside their 
medical relevance, these compounds are used in many industrial, agricultural and forest 
applications [4]. About 100.000 secondary metabolites of a molecular weight below than 
2500 have been characterised, among them approximately 50.000 from microbial sources 
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[10]. New microbial bioactive products continue to be discovered at an amazing pace: 200-
300 per year in the late 70s, increasing to 500 per year by 1997 [4]. 
Antibiotics are perhaps the most widely studied type of secondary metabolites with 12000 
antibiotics known up to 1995. Again, microbial cells are the most importance source of this 
type of secondary metabolites. Indeed, from the known antibiotics 55 % are produced by 
filamentous bacteria of the genus actinomyces, 11 % from other actinomyces, 12 % from 
non-filamentous bacteria and 22 % from filamentous fungi.  
Different alternatives for improving production of secondary metabolites with different 
activities for biotechnological applications have been extensively investigated. Since, 
biotechnology industry is based on harnessing the metabolic activities of different 
organisms to produce a wide variety of diverse compounds, which are used by other 
industries. Two methods have been applied, optimisation of fermentation process and 
improvement of strains [11]. The microbial production of secondary metabolites is 
extremely sensitive to environmental factors or culture conditions [12]. For instance, the in 
vitro production of most antibiotics depends on the composition of the culture medium in 
which the producer organism is grown. For this reason, medium optimisation has been the 
standard procedure for optimising antibiotic production.  
Overproduction of secondary metabolites is a complex process and the successful 
development of improved strains requires knowledge of physiology of the microbial 
producer and pathway regulation and control of the product. Recently, research efforts 
have been devoted to elucidate, at the molecular level, the regulatory mechanisms involved 
in the control of the biosynthesis of antibiotics [13]. Most of the work performed in this 
field has been focused in antibiotics produced by fungi and actinomycetes. For these, a 
number of biochemical and genetic controls have been described to optimise the levels at 
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which the antibiotics are produced in a specific media [14].  
 
1.2. History of secondary metabolites 
 
Secondary metabolites have been used for centuries. Microorganisms, and more 
specifically their products, were used in food conservation and production of wine, cheeses 
and bread. For example, as a method of preservation, milk was converted to lactic acid to 
make yoghurt.  
In the same form, secondary metabolites with antimicrobial properties have been used for 
many years. Indeed, moldy cheese, meat and bread were employed in folk medicine to heal 
wounds [5, 15]. Yet, it was not until 1870s, that Tyndall, Pasteur and Roberts reported the 
antagonistic effects of some organisms on others. In fact, the antibiotics era began in 1929 
with the penicillin discovery by Fleming. However, antibiotic research and industry only 
flourished after the commercial production of penicillin in the 1940s [5, 16]. In spite of 
this, until 1970 only two classes of naturally occurring β-lactam antibiotics, penicillins and 
cephalosporins, were known. Although, with the advent of new screening and isolation 
techniques, a variety of β-lactam-containing molecules [17] and other types of antibiotics 
have been identified. In fact, screening of microorganisms for production of antibiotics has 
provided the cornerstone of antibiotic research programs for the past thirty years. The great 
majority of such studies have been carried out with fungi and actinomycetes, which are 
capable of producing natural products with widely divergent chemical structures. 
Some peptides have shown antibiotic properties; over 400 with antimicrobial activity have 
been identified from extremely diverse sources including plants, insects, bacteria, and 
vertebrates [18]. Some of these peptides are induced at epithelial surfaces in response to 
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invading organisms. Many of these antimicrobial compounds kill microorganisms by 
causing membrane permeabilization, although not necessary as their sole mode of action 
[19, 20]. Finally, several antimicrobial peptides are additionally involved in chemotaxis 
promoting wound healing. In addition, some contribute to adaptative immunity by 
mobilizing memory T cells and immature dendritic cells. 
Parallel to the screening for new antibiotics, efforts have been focused in finding low 
molecular weight secondary metabolites with other biological activities. Among others, 
secondary metabolites with activity as enzyme inhibitors, plant growth stimulators, 
herbicides, insecticides, antihelmintics and immunosuppressant have been obtained. Two 
main strategies have been used during the screening process of these compounds. First, the 
screening of known secondary metabolites which had failed as useful antibiotics and 
second, screening of unknown compounds using new technologies for detecting inhibition 
of enzymes and biological activities in other targets. 
Secondary metabolites play a significant role in clinical practice due to their activity as 
antimicrobials used in the treatment of microbial induced infections. But apart from these 
activities secondary metabolites possess other pharmacological activities useful in the 
medical field, some act as carcinostatics. The best antitumor substances are mithramycin, 
bleomycin, daunomycin and adriamycin [16]. Other have properties as anabolics, 
anesthetics, anticoagulants, anti-inflammatories, immunosupressants (cyclosporin A and 
tacrolimus), hemolytics, hypocholesterolemics (statin), and vasodilatories. 
 
1.3. Function and importance of secondary metabolites 
 
Several hypotheses exist about the origin and function of secondary metabolites. The most 
accepted considers secondary metabolites as waste products that under the pressure of 
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natural selection have evolved as messenger molecules which must endure long enough to 
shuttle between the various components of the microbial community. This fact, would 
explain the secondary metabolites tendency to be small organic molecules, as a natural 
consequence of their functions [21]. 
The explicit role of secondary metabolites in microbe-microbe interactions is unknown, 
specially how their production affects the community ecology. In fact, the notion that 
microbial antibiotics are employed by the producing organisms to adversely affect their 
competitors is cited. Nevertheless, it is accepted that they are beneficial to the producer not 
only against microbial competitors but also against other organisms including parasites, 
plants, insects and even superior animals [5, 22].  
An interesting property common to most potent antibiotics is that at very low 
concentrations, they act as growth stimulants [4]. This raises an interesting possibility that 
some secondary metabolites may actually stimulate growth of other microorganisms 
antagonistic to the growth of the competitors of the secondary metabolite-producing 
organisms. The presence of complex biosynthetic pathways for production of complex 
antibiotics suggest that they must have an important role in microbial survival, either as 
inhibitors of other competing organisms or as regulatory effectors during some stage of the 
cell differentiation process, since sensitive organisms need to evolve only a single enzyme 
of any several reaction types to inactivate most antibiotics [4]. 
Nowadays, several arguments support the hypothesis that secondary metabolites improve 
the survival of the producer in competition with other living species. These arguments are 
as follows [5]: 
a) Secondary metabolites act as an alternative defence mechanism, because only the 
organisms lacking an immune system are prolific producers of these compounds. 
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b) They have sophisticated structures, mechanisms of action, and complex and 
energetically expensive pathways. 
c) Secondary metabolites act in the competition between microorganisms, plant and 
animals. 
d) They are produced by biosynthetic genes clusters, which would only be selected if the 
product conferred a selective advantage. Some particularities of these genes clusters are the 
absence of non-functional genes and the presence of resistance and regulatory genes. 
e) The production of secondary metabolites with antibiotic activities is temporarily related 
with sporulation when the cells are particularly sensitivity to competitors and requiring 
special protection when a nutrient runs out. 
Furthermore, the wide diversity of secondary metabolites suggests a broad range of 
functions. Nevertheless, these functions could depend on the conditions, optimal or not, 
surrounding the producer microorganism. Finally, due to their crucial importance the study 
and exploitation of secondary metabolites continue to progress despite the lack of 
agreement regarding why microbes produce such chemical diversity of antimicrobial 
compounds. 
 
1.4. Genetic of secondary metabolites 
 
The genes regulating and ensuring synthesis of secondary metabolites and their expression 
can be grouped in 5 classes: I) structural genes, that code for enzymes involved in the 
biosynthesis; II) regulatory genes, that determine the induction or repression of the 
structural genes; III) genes that determine the resistance of the producing organism; IV) 
genes controlling the permeability to the compound and V) genes that control primary 
pathways. The genetic regulation of all above mentioned genes is highly complicated 
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because many environmental and microbial factors affect the production of these 
compounds. 
 
The genes coding for biosynthesis of secondary metabolites have some features that can be 
summarized as follows: 
a) They are arranged in clusters on the chromosome. 
b) These genes are organized in several transcription units not in a single operon. 
c) Within each cluster at least some transcription units are controlled by the products of 
pathway specific regulatory genes. 
d) Specific regulatory genes are situated in the closest proximity of biosynthetic genes. 
e) Gene expression is primarily controlled at the level of transcription but also at the level 
of translation. 
f) Genes coding for resistance to a given metabolite are closely linked with the cluster of 
biosynthetic genes. Usually genes coding for at least two different types of resistance to a 
produced secondary metabolite can be found within the gene cluster. 
g) Expression of genes coding for a secondary metabolite, including genes coding for 
resistance to it, is controlled by central overruling regulatory circuits often exhibiting 
pleiotropic regulatory effects [12, 23]. 
 Functionally related genes are on the chromosome suggesting that at least part of their 
evolution has occurred as a unit. Evolutionally, two types of gene clusters that produce 
secondary metabolites can be described: first, a gene cluster might contain many genes, 
some of which give rise to chemical transformations of substrates and many other that do 
not. This type of cluster would be indicative of a natural product which has not been 
selected for and which is not functional. Second, a gene cluster might contain only genes 
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that code for enzymes of a particular biosynthetic pathway, resistance genes and regulatory 
factors, and no “junk” genes. This type of gene cluster indicate a natural product that has 
been selected for and which has had a beneficial function for the producer organism [3, 
22].  
 Since antimicrobial producing genes are tightly clustered in the microbial chromosomes, 
both gene replacements and coregulation of all the genes necessary for antibiotic formation 
are facilitated [24]. In fact, by applying DNA recombinant technologies, a large amount of 
genes coding for enzymes involved in synthesis of secondary metabolites have been cloned 
in order to improve expression levels. In addition, with the genomic sequences of several 
antibiotic-producing microbes becoming available, there has been much interest in 
combinatorial biosynthetic approaches. Indeed, by manipulating the genes of antibiotic 
biosynthesis pathways, hybrid or variant antibiotics with novel properties and efficacies 
against resistant pathogens could be generated.  
Specifically, the polyketide antibiotics, both the aromatic family represented by 
tetracyclines, and the macrolide family represented by erythromycins, are produced by 
clustered genes. In contrast, the aminoglycosides are not produced by corregulated genes, 
which are dispersed throughout the genomes of the producer microorganism [24]. Finally, 
contrary to the above-mentioned compounds, peptide based antibiotics as vancomycins, 
bacitracins, and ß-lactam antibiotics are synthesised on non-ribosomal peptide synthetase 
(NRPS) assembly lines. However, they also have been considered candidates for 
combinatorial biosynthesis approaches as their biosynthesis has some similarities with the 
one of the poliketides [24]. 
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1.5. Microorganisms producing secondary metabolites 
 
As it was mentioned above, secondary metabolites are common to organisms that lack an 
immune system thus are rarely produced by higher animals [22]. Indeed, these compounds 
are mostly biosynthesised by bacteria, fungi, algae, corals, sponges, plants and lower 
animals. Actually, filamentous microorganisms are the main source of secondary 
metabolites with nearly 75 % of all described antibiotics being produced by actinomycetes 
and 17 % by molds. Moreover, approximately 40 % of the filamentous fungi and 
actinomycetes produce antibiotics when freshly isolated from nature. Some isolates of 
several Streptomyces species can produce more than 180 different secondary metabolites 
[5].  
Bacteria that show high natural products production are those belonging to the genus 
Bacillus. Several antibiotics have been isolated from different Bacillus strains, 
moenomycins, difficidins, bacillomycins and bacillaenes are part of this wide variety [25-
27]. Myxobacteria is yet another genus of bacteria with interesting antibiotic 
productivities. For instance, Reichenbach et al. [28], found that approximately 80 % of the 
isolated Myxobacteria produced compounds with antibiotic activity, many of them with 
antifungal activity. These data were later confirmed by Foster et al. [29] who reported that 
77 % of soil Myxobacteria showed antibiotic activity against Micrococcus luteus.  
An immense variety of active secondary metabolites with different properties have been 
isolated from several microbial species belonging to a wide range of genera. In Table 1 are 
listed some of the most important secondary metabolites with biological activities 
produced by microorganisms. 
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Table 1.  Microbial secondary metabolites with important biological activities 
 
Compound Producer Biological activity 
Amphotericin B Streptomyces nodosus Antifungal 
Bialaphos Streptomyces hygroscopicus Herbicide 
Cephalosporin Cephalosporium chrysogenum Antibiotic 
Chlortetracycline Streptomyces aureofaciens Antibiotic, Growth promotant 
Cyclosporin A Trichoderma polysporum Immunosuppressant 
Daunorubicin HCl Streptomyces sp. Antitumoral 
Doxorubicin HCl Streptomyces peucetius Antitumoral 
Erythromycin A Streptomyces erythreus Antibiotic 
Gentamicin  Micromonospora purpurea Antibiotic 
Kanamycin  Streptomyces canus Antibiotic 
Lasalocid sodium Streptomyces sp. Growth promotant 
Lincomycin HCl Streptomyces lincolnensis Antibiotic 
Mitosane Streptomyces caespitosus Antitumoral 
Monensin sodium Streptomyces cinnamonensis Growth promotant 
Oxytetracycline Streptomyces rimosus Antibiotic, feed additive 
Paclitaxel Taxomyces andreanae Antitumoral 
Penicillin Penicillium chrysogenum Antibiotic 
Rifamycin Amycolatopsis mediterranei Antibiotic 
Salinomycin Streptomyces albus Growth promotant 
Spiramycin Streptomyces ambofaciens Antibiotic 
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Continued Table 1. 
Compound Producer Biological activity 
Statin Aspergillus terreus Hypocholesterolemic 
Streptomycin sulfate Streptomyces griseus Antibiotic 
Tacrolimus Streptomyces Immunosuppressant 
Teicoplanin Actinoplanes teichomyceticus Antibiotic 
Tetracycline HCl Streptomyces aureofaciens Antibiotic 
Tylosin phosphate Streptomyces cirratus Growth promotant 
Vancomycin HCl Amycolatopsis orientalis Antibiotic 
 
1.6. Antimicrobials: modes of action 
 
Antimicrobials and specifically antibiotics are define as low molecular weight organic 
natural products made by microorganisms which are active against other microorganisms 
at low concentration [4]. This activity develops through a limited number of mechanisms, 
antimicrobials interfere with cell wall synthesis, cell membrane integrity, protein synthesis, 
DNA replication and repair, transcription and intermediate metabolism (Figure 1). 
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Figure 1.  Site of action of common antimicrobial agents. 
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The compounds blocking the cell wall biosynthesis inhibit enzymes involved in synthesis 
of different components of the cell wall. While the compounds interfering with cell 
membrane integrity disorganize the structure or inhibit the function of bacterial 
membranes. Antimicrobials affecting the protein synthesis act impairing the ribosomal 
subunits, binding to 50S prevents the translation and binding to 30S causes wrong 
translation, producing toxic and altered proteins. Compounds having an effect on DNA 
replication and repair, inhibit enzymes as gyrase and topoisomerase and N-
methyltransferase. Similarly, compounds affecting transcription inhibit the subunits of the 
bacterial RNA polymerase blocking the entry of the first nucleotide necessary to activate 
the polymerase. Finally, some antimicrobials interfere with intermediate metabolism by 
inhibiting enzymes involved in the biosynthesis of different substances. In Table 2 are 
listed some of the more common classes of antimicrobials and their mechanisms of action 
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Table 2.  Common classes of antimicrobials and their mechanisms of action. 
Class Family* / examples Mechanism 
Penicillins 
Methicillin 
Aminopenicillins 
Cephalosporins 
Monobactams 
Aztreonam 
β-Lactams 
Carbapenems 
Imipenem 
Meropenem 
Peptides Glycopeptides 
Vancomycin 
Teicoplanin 
Cell wall synthesis Inhibitors
Tetracyclines 
 
Tetracycline 
Minocycline 
Macrolides Erythromycin 
Azithromycin 
Aminoglycosides Gentamicin 
Tobramycin 
Protein synthesis inhibitors 
Sulfonamides Sulfadiazine 
Sulfisoxazole 
Trimethoprim Trimethoprim 
Sulfamethoxazole 
Folic acid synthesis 
inhibitors 
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Continued Table 2. 
Class Family* / examples Mechanism 
Nitrofurantoin Nitrofurantoin DNA damage 
Metronidazol Metronidazol 
Quinolones Ciprofloxacin 
Ofloxacin 
Norfloxacin 
DNA synthesis inhibitors 
 
*Families of antibiotics are written in bold 
 
1.7. Development of resistance to antimicrobial agents 
 
A few decades after the introduction of antibiotics into clinical practice, resistance by 
pathogenic bacteria has become a major health concern. Indeed, while in the mid 1970s 
infectious diseases were considered virtually conquered [30], actually many gram positive 
bacteria and gram negative opportunistic pathogens are becoming resistant to virtually 
every clinically available drug [31, 32]. The use of antimicrobial drugs for prophylactic or 
therapeutic purposes in human and veterinary or for agricultural purposes, has provided the 
selective pressure favouring the survival and spread of resistant organisms. Staphylococcus 
aureus, for instance, a virulent pathogen that is responsible for a wide range of infections 
including pimples, pneumonia, osteomyelitis, endocarditis and bacteremia, has developed 
resistance to most classes of antibiotics. Methicillin-resistant S. aureus (MRSA) strains 
appeared in the hospital environment after introduction of the semi-synthetic penicillin and 
methicillin, being vancomycin the last chance for MRSA treatment [33]. Certainly, 
Vancomycin is the last tool for the treatment of the infections caused by the resistant gram 
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positive microorganisms. Indeed, vancomycin resistance is difficult to acquire because is a 
complex system involving up to 7 genes. However vancomycin-intermediately-sensitive S. 
aureus were first isolated in 1997 in Japan [34] and later in other countries [35]. In fact, 
vancomycin-resistant clinical isolates have been recently reported [36-38]. Thus currently, 
no antibiotic class is effective against multi-resistant S. aureus infections and new 
antibiotics or alternative chemotherapeutic strategies are urgently needed. 
Enterococci are responsible for urinary tract, wound, intraabdominal, and pelvic infections 
[39]. The increase of vancomycin-resistant enterococci (VRE) as important agents of 
nosocomial infections is cause of great concern [40, 41]. It is thought that a selective 
pressure favouring the survival and spread of VRE was the consequence of the use of 
antibiotics in food and agricultural practices [42]. Actually, there are no effective 
antibiotics currently available for such organisms. Even worst, vancomycin-resistance is 
often associated with multiple-drug resistance [40, 41, 43, 44].  
 
Another cause of great concern is the gram-negative antibiotic-resistant opportunistic 
pathogens. These bacteria, like Pseudomonas aeruginosa, are common environmental 
organisms, which act as opportunistic pathogens in clinical cases where the defence system 
of the patient is compromised [45]. For instance, over 80 % of cystic fibrosis (CF) patients 
become chronically infected with P. aeruginosa. In addition, other intrinsically antibiotic-
resistant organisms such as Burkholderia cepacia [46] and Stenotrophomonas maltophilia 
[47] are emerging as opportunistic pathogens. Interestingly, changes in the bacterial 
phenotype have been observed concomitant with the appearance or increase of antibiotic 
resistance. Indeed, in CF infections, initially, strains are non mucoid, but over time a 
mucoid population showing slow growth phenotype with a increased capability to form 
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biofilms, the small colony variants (SCV), develops [48]. This ability is considered a major 
virulence trait because the bacteria are protected from adverse environmental conditions as 
well as from biological and chemical antibacterial agents [49]. Thus, new therapeutic drugs 
and/or approaches are needed to improve the management of these diseases and overcome 
these problems [50, 51]. 
In conclusion, the appearance of multiresistant pathogenic strains has caused a therapeutic 
problem of enormous proportions. For instance, they cause substantial morbidity and 
mortality specially among the elderly and immunocompromised patients. In response, there 
is a renewed interest in discovering novel classes of antibiotics that have different 
mechanisms of action [23, 39].  
 40
2. GOAL OF THE STUDY 
 
The main aim of this study was the discovery secondary metabolites with antibiotic 
activity against microbial pathogens resistant to antibiotics currently used in the clinical 
practice. 
 
To achieve this goal the following specific objectives were pursue: 
 
- Identification of active secondary metabolites contained in MeOH extracts produced by 
2048 isolates obtained from a wide variety of environmental sources. 
 
- Optimisation of cultivation parameters in order to improve the yields and increase the 
number of secondary metabolites available from different microbial sources. 
 
- Chemical characterisation of secondary metabolites with high biological activities . 
 
- Purification and structure elucidation of novel active secondary metabolites. 
 
- Chemical and biological characterisation of the new compound, 7-O-malonyl macrolactin 
A, showing activity against bacterial pathogens. 
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3. MATERIALS AND METHODS 
 
3.1. Microorganisms 
 
3.1.1. Isolation, origin and maintenance of producing microbial strains 
Bacterial strains were obtained from a variety of environmental sources from different 
geographical areas (Kenya, Indonesia, Italy, Vietnam, Mexico and Germany). The strains 
were isolated in the Department of Enviromental Microbiology, German research center 
for Biotechnology - GBF (Braunschweig, Germany) in the course of its studies on the 
structure and function of natural microbial communities. Particularly were included into 
the study, the organisms that inhabit extreme or poorly explore areas, like hypersaline or 
volcanic environments. As an alternative, environmental samples were used as source of 
microorganisms used in this study. For their isolation 10 –20 mg of the samples were 
incubated in 50 ml of phosphate-buffered saline (PBS) 1X solution at room temperature 
with shaking for 1h. 100 µl of the PBS containing the sample were platted in petri dishes 
with LB agar medium and incubated over night at 30°C. The isolated colonies were 
cultivated in separated plates and stored in liquid LB with 20 % of glycerol at -80°C. 
Altogether, 2048 environmental strains were tested for biologically active secondary 
metabolites. Strains showing biological activities were identified using 16S rRNA 
sequence analysis.  
 
3.1.2. Target microorganisms 
Several target microorganisms were used to assess the antimicrobial activity of the MeOH 
extracts obtained from environmental isolates. Bacterial target strains were growth over 
night at 37°C in Luria Broth (LB) except for S. aureus, E. faecalis and E. faecium, which 
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were grown on Columbia blood agar. Yeast and fungi strains were growth in M90 and 
Potato Dextrosa agar media, respectively. The assessment of the antimicrobial activities 
was performed in Mueller-Hinton (MH) broth and agar (Difco). The species, origin and 
sources of the target microorganisms are listed in Table 3.  
 
Table 3.  Microorganisms used as target to assess the antibacterial activity of the produced 
microbial extracts. 
Strains Origin Remarks 
Staphylococcus aureus GBF Collection  
Staphylococcus aureus DSM 2569  
Staphylococcus aureus DSM 1104  
Staphylococcus aureus 3 clinical isolates MRSA 
Enterococcus faecalis ATCC 29212  
Enterococcus faecalis  E305 clinical isolate VRAS 
Enterococcus faecium E315 clinical isolate VRAR 
Escherichia coli DSM 498  
Pseudomonas aeruginosa DSM 1117  
Pseudomonas aeruginosa 3 isolates from CF patients WT- antibiotic multiresistant 
Pseudomonas aeruginosa 3 isolates from CF patients SCV- antibiotic multiresistant
Pseudomonas aeruginosa  12 isolates from CF patients NM - antibiotic multiresistant
Burkholderia cepacia  3 isolates from CF patients WT - antibiotic multiresistant
Burkholderia cepacia  3 isolates from CF patients SCV- antibiotic multiresistant
Stenotrophomonas maltophilia 15 clinical isolates antibiotic multiresistant 
Candida albicans DSM 11225  
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Continued Tabla 3. 
 
Strains Origin Remarks 
Candida glabrata DSM 11226  
Candida tropicalis DSM 5991  
Candida parapsilosis DSM 5784  
Candida krusei DSM 6128  
Pichia anomala DSM 70263  
Metschnikowia pulcherrina DSM 70321  
Schizosaccharomyces pombe Tü 501  
Botrytis cinerea DSM 877  
Fusarium fujikuroi DSM 893  
Penicillium digitatum DSM 62840  
 
MRSA: methicillin resistant Staphylococcus aureus 
VRAS: vancomycin resistant-ampicillin sensitive 
VRAR: vancomycin resistant-ampicillin resistant 
WT: wild type  
SCV: Small colony variants 
CF: Cystic fibrosis 
NM: Non mucoid 
All clinical isolates from CF patients and S. maltophilia were kindly provided by Susanne 
Häußler (Department of Medical Microbiology, Medizinische Hochschule Hannover), 
except for P. aeruginosa non-mucoid strains provided by Prof. Niels Høiby (Department of 
Paediatrics, Danish Cystic Fibrosis Center, Rigshospitalet, Copenhagen O, Denmark). 
 
3.2. Antibiotics 
 
Several commercial antibiotic discs (BioMerieux and Rosco) were used to evaluate and 
control the pattern of antibiotic sensitivity of the different target strains. Erythromycin 
(ERY), Vancomycin (VAN), Ampicillin (AMP), Gentamicin (GEN) and Miconazole 
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(MCZ) were obtained from Sigma-Aldrich. Stock solutions were freshly prepared at 10 
mg/ml in sterile distilled water, except for erythromycin, which was prepared in ethanol. 
 
3.3. Production and extraction of secondary metabolites 
 
Different solid and liquid media were used to cultivate the environmental strains. The 
medium selected for each strain was chosen according their origin of the isolate during the 
preparation of the first extract for the screening (see media in Appendix). Culture extracts 
were obtained as described by Sasse et al [52]. Flasks containing 200 ml of medium were 
inoculated with 500 µl of microbial preculture. At the same time, an adsorbent resin 
amberlite XAD-16 (Rohm & Haas, Germany) was added (4 %) and the flasks were 
incubated at 30°C and 120 rpm, for 7 days. The resin was recovered from the culture broth 
by decantation, transferred into a column and washed with 50 % aqueous MeOH. 
Absorbed products were eluted with 100 % MeOH, concentrated by rotavaporation and 
finally resuspended in 2 ml of MeOH. MeOH extracts were stored at –80 or –20°C.  
 
3.3.1. Extraction of macrolactin compounds 
Specifically, for the extraction of the macrolactin compounds, MeOH extracts were 
obtained from 7 day cultures of B. subtilis MIK-SM 2586 in OM medium. After MeOH 
evaporation, the remaining aqueous mixture was extracted 4 times with ethyl acetate. 
Evaporation of the solvent under reduced pressure provided approximately 300 mg of oily 
residue from a total of 4 L of culture. This was resuspended in MeOH and partitioned four 
times with the same volume of n-heptane to remove the more lipophilic 
products/contaminations. 
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3.4. Biological tests 
 
3.4.1. In vitro antibacterial activities 
The in vitro antibacterial activities were evaluated using a disc diffusion test on solid 
medium and a microdilution test in liquid medium. For the agar diffusion test, sterile discs 
(Schleicher & Schuell, Germany) impregnated with 10 µl of MeOH extract or a solution of 
purified macrolactins (50 µg final macrolactin concentration on the disc) was placed on the 
dried surface of MH agar plates. The plates were previously inoculated with a standardized 
suspension (105 CFU/ml) of the different target microorganisms. The suspensions were 
prepared from a one-day culture in LB liquid medium. After overnight incubation at 30°C, 
the diameter of the resultant zones of inhibition of growth around the disc was measured. 
Microdilution tests were performed using MH broth. Microtiter plates containing 50 µl of 
twofold serial dilutions of each antimicrobial agent or MeOH extract per well were 
inoculated with 50 µl of a bacterial suspension to yield the appropriate density (1 to 5 x 105 
CFU/ml). In parallel MeOH dilutions and MH broth alone were used to control the 
microbial growth. The lower concentration of antibiotic or the higher dilution of MeOH 
extract that were able to inhibit the target microbial growth was recorded after 18 h of 
incubation at 37°C. 
 
3.4.2. Antifungal and antiyeast activities 
Antifungal and antiyeast activities were evaluated using an agar diffusion test, following a 
similar procedure as for antibacterial activity (Numeral 3.4.1.). These experiments were 
carried out by Olga Golyshina (Division of Microbiology, GBF). The media used were 
M90, for antifungal and MH for antiyeast assays. The time of incubation was variable (1-3 
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days) depending on the rate of the growth of the fungi or yeast. 
 
3.4.3. Insecticidal activity 
Insecticidal activity of the MeOH extracts was tested against four insects targets belonging 
to the order Lepdidoptera (Spodoptera frugiperda), Diptera (Musca domestica and 
Anopheles albimanus) and Coleoptera (Tenebrio molitor). The experiments were 
performed in the “Corporacion para Investigaciones biologicas” (Medellin, Colombia). 
 
3.4.3.1. Insecticidal activity against mosquitoes 
Five first instar mosquito larvae of Anopheles albimanus were placed in 24 well plates with 
960 µl of sterile water, to which 40 µl of the extract were added. Water, and MeOH/water 
were used as controls. Mortality of A. albimanus larvae was scored after 24 h of incubation 
at 30°C. 
 
3.4.3.2. Insecticidal activity against Spodoptera frugiperda 
A total of 40 µl of the MeOH extract were added to the surface of a beans based diet 
served in disposable cups. After 4 hours, five first instar S. frugiperda larvae were placed 
on the surface of the diet. Sterile phosphate-buffered saline (PBS) and MeOH were used as 
controls. Mortality of S. frugiperda larvae was scored after 72 h. 
 
3.4.3.3. Insecticidal activity against Musca domestica  
The activity of the MeOH extracts was evaluated using the filter paper technique. Filter 
paper was placed in a petri dish and moistened with 40 µl of MeOH extract diluted in 360 
µl of distilled water. Three M. domestica larvae were placed in each dish. Activity was 
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recorded after 72, 144 and 192h at 17°C by scoring larval mortality, teratological effects 
and adult emergence. Water and MeOH / water were used as controls. 
 
3.4.3.4. Insecticidl activity against Tenebrio molitor 
10-20 mg artificial diet for T. molitor (corn meal 95 %, yeast 5 %) were moistened with 40 
µl of each MeOH extract dissolved in 1 ml of sterile water and lyophilised over night. The 
mix was placed in 24 wells plates. Two neonate larvae of T. molitor were transferred to 
each well. The bioassay was observed after 7 days at room temperature. Water and MeOH 
/ water were used as controls. 
 
3.4.4. Cytotoxic activity 
The eukaryotic cell cytotoxicity assay is used for evaluating the potential toxic properties 
of the compounds. Cytotoxicity includes changes in the normal cellular growth or 
expression which alters the ability of the cell to reproduce itself or maintain its normal 
tissue specific function. The cell proliferation process can be also promoted or retarded. 
Cytotoxicity assays were performed by Dr. Gabriella Molinari (Division of Microbiology, 
GBF). HeLa human cervical carcinoma cells and L929 mouse fibroblast were cultured in 
DMEM (Gibco) low and high glucose, respectively. These media were supplemented with 
10 % (v/v) fetal bovine serum (Gibco) and maintained at 37 °C with 5 % CO2. Cells were 
removed from monolayer stock cultures with trypsin, with and without EDTA (Gibco), for 
HeLa and L929, respectively. The cells were counted, diluted to obtain 104 cells/ml and 
inoculated in microtiter plates alone and in the presence of serial dilutions of the MeOH 
extracts or purified compounds. MeOH was used as control. Morphological changes in 
cells were evaluated by phase-contrast microscopy after 1, 2 and 5 days of incubation. 
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Finally, after 5 days, cell counts were obtained using the CyQUANT cell proliferation 
assay (Molecular Probes), a highly sensitive, fluorescence-based microplate assay for 
determining numbers of cultured cells [53]. The assay employs CyQUANT dye, which 
produces a large fluorescence enhancement upon binding to cellular nucleic acids that can 
be measured using fluorescein excitation. The fluorescence emission of the dye-nucleic 
acid complexes correlated linearly with the cell number. [53]. The assay was performed 
according to manufacturer instructions measuring fluorescence with an excitation of 480 
nm and emission of 520 nm with a fluorometric plate reader (Titertex Fluoroskan II).  
 
3.4.5. Minimal Inhibitory Concentrations of 7-O-malonyl macrolactin A 
The standard twofold serial microdilution method described by the National Committee for 
Clinical Laboratory Standards (NCCLS) [54] was performed for the assessment of the 
minimal inhibitory concentrations (MICs). For this test 96 wells plates containing 100 µl 
per well of MH broth with purified macrolactins or commercial antibiotics were used. In 
parallel MeOH dilutions and MH broth alone were used as microbial growth controls. Each 
well was inoculated with 105 cells/ml of the target microorganisms. The MIC was defined 
as the lowest antibiotic concentration that completely prevented visible growth after 
incubation at 37°C for 20h. 
 
3.4.6. Kinetics of growth at sub-Minimal Inhibitory Concentrations of 7-O-malonyl 
macrolactin A 
During the MIC determination, a strong reduction of microbial growth, but not full 
inhibition, was observed at sub-MICs of 7-O-malonyl macrolactin A (7-O-m). Thus, 
growth kinetics of the selected target microorganisms was evaluated under these 
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concentrations. Fresh MH broth with appropriate 7-O-m concentration was inoculated to 
about 106 CFU/ml from overnight cultures. The test tubes were incubated at 37°C and 150 
rpm. Aliquots of the culture were removed at 0, 1, 2, 4, 6, 8 and 24 hours, and dilutions 
were plated in LB agar medium using a spiral plater (Spiral Biotech). After 24 hours 
incubation at 37°C, colony counts were determined using a laser colony counter (CASBA 
4, Spiral Biotech). Finally, growth profiles were constructed. 
 
3.4.7. Post-Antibiotic effect measurements of 7-O-malonyl macrolactin A 
Post-antibiotic effect (PAE) is a term used to describe suppression of bacterial growth that 
persist after brief exposure of organisms to antimicrobials. PAE measurements at sub-
MICs were determined with the method of Craig and Gudmundsson [55]. To induce PAE, 
7-O-m was added to tubes containing MH broth to give a final concentration 4 times the 
sub-MIC. These tubes were inoculated with overnight cultures of MRSA3 and VRAR E. 
faecium at 106 CFU/ml and incubated at 37°C. After 1h the samples were diluted 1:1000 in 
drug free MH broth warmed at 37°C in order to remove the antibiotic. Test tubes without 
antibiotic were used as controls. The treated and control cultures were then incubated at 
37°C. Viability counts were determined before exposure and immediately after dilution (0 
h) and then 1, 2, 4 and 6 h by plating in MH agar medium using a spiral plater (Spiral 
Biotech) and incubated for 24 hours at 37°C. Colony counts (CFU/ml) were determined 
using a laser colony counter (CASBA 4, Spiral Biotech). 
The PAE was defined by the equation: PAE = T - C, where T is the time required for 
viability counts of an antibiotic exposed culture to increase by 1 log10 above the counts 
observed immediately after dilution and C is the corresponding time for the growth control 
[43]. 
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3.4.8. Transmission electron microscopy 
For transmission electron microscopy (TEM), 7-O-m was added to tubes containing MH 
broth to give a final concentration equal to 4 times the sub-MIC. The tubes were inoculated 
with overnight cultures of MRSA3 and VRAR E. faecium at 106 CFU/ml and incubated at 
37°C for 4 h. Tubes without antibiotic were used as controls. The cells were harvested by 
centrifugation at 12000 rpm and fixed with 1 % (v/v) glutardialdehyde in phosphate-
buffered saline (PBS: 20 mM sodium phosphate, 150 mM NaCl, pH 7±2). After washing 
in 0±1x PBS, the cells were post-fixed with 1 % OsO (w/v) in 0±1 M sodium cacodylate, 
pH 7±0, overnight at 4°C. Cells were immobilized in 2 % (w/v) Difco agar in PBS. 
Dehydration in an acetone series (30, 50, 70, 90, 100 and 100 %, v/v) was done at ambient 
temperature, requiring 20 min for each dehydration step. Infiltration with an embedding 
resin/acetone mixture (1:1, v/v) was done at ambient temperature overnight, followed by 
pure resin infiltration overnight and finally for 4 h [56]. Probes were transferred into a 
gelatine capsule and filled with resin monomer. Polymerization was done for 8 h at 70 °C. 
Ultrathin sections were cut with a diamond knife using the Leica Ultracut ultramicrotome 
and were picked up with Formvar-coated grids (300 mesh, Cu). Sections were poststained 
for 10 min with 3 % (w/v) aqueous uranyl acetate and for 5 min with 0±5 % (w/v) lead 
citrate as described by Reynolds [57]. The samples were examined using a transmission 
electron microscope (Zeiss CEM 902, conventional mode, 30 lm objective aperture, 80 kV 
acceleration voltage). Electron micrographs were taken digitally with a high resolution 
CCD camera (Proscam). 
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3.5. Identification of the active compounds 
 
Different strategies were used for determining the chemical nature of the active substances 
contained in the MeOH extracts with biological activities. 
 
3.5.1. Thin Layer Chromatography for determination of the active substance 
Thin layer chromatography (TLC) was carried out using TLC aluminium sheets silica gel 
60 F 254 (Merck 05554) or TLC plates SIL 20 UV 254 (Macherey-Nagel). Separation of 
the compounds present in the active MeOH extracts was achieved by applying 3 µl of the 
extract to a silica gel TLC plate, which afterwards, was immersed in the appropriate 
solvent (Table 4). Afterwards, the plate was covered with MH agar, inoculated with the 
target strain and incubated over night at 30°C. Inhibition zones resulted in the area in 
which biologically active compounds diffused. These inhibition zones were used to define 
the areas to scrape out of a parallel TLC carried out in the same conditions. The active 
compound was eluted with MeOH.  
 
Table 4.  Solvents used for TLC.  
 
Mixture Concentrations 
CH2Cl2: MeOH 80:20 to 90:10 
Ethylacetate:MeOH:H2O 85:15:1 
CHCl3:MeOH:NH3+ 65:25:8 to 65:25:12 
MeOH:H2O 80:20 
 
TLC of the MeOH extracts was carried out in four solvents depending on the chemical 
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properties of the active compound. On the basis of the results of the first running, either 
different concentrations of the same solvent or other solvents were employed for efficiently 
separation and isolation of active compounds. 
 
3.5.2. Silica gel column chromatography for determination of the active substance 
Active compounds were purified by column chromatography on silica gel with the 
appropriate solvent. One ml of extract was placed in a glass column of 50 cm previously 
equilibrated and eluted with 3 volumes of 4 different concentrations of the same solvent. 
Around 50 fractions of 5 ml each were collected and their antimicrobial activity tested. The 
active fractions were identified and concentrated to be further characterised. 
 
3.5.3. High performance liquid chromatography for determination of the active 
substance 
High performance liquid chromatography (HPLC) was carried out using a Waters HPLC 
system 2690 equipped with a pump and a Water photodiode array detector (PDA 996) with 
variable wavelength detector (220-800nm). The column used was a Nucleosil 100-5 C18 
column (250/4 mm, Macherey-Nagel). The solvents used were A: 0.5 % Formic acid/H20 
and B: 0.5 % Formic acid/Acetonitrile. Gradient 10 % B 0 min; 10 % B 5 min; 20 % B 10 
min; 30% B 15 min; 45 % B 20 min; 60 % B 25 min; 85 % B 28 min; 100 % B 30 min; 10 
% B 32 min; the flow rate was 1.0 ml/min. All solvents were degassed prior to use. 50 µl 
of the MeOH extract were injected and 60 fractions (every 30 seconds) were collected with 
a Waters fraction collector. The biological activities of each fraction were compared with 
the activity of the MeOH extract using the agar diffusion test. Fractions showing biological 
activity were identified in the chromatogram and the corresponding UV spectra analysed. 
 54
3.5.4. Identification of the antimicrobial substance by HPLC-UV-MS  
HPLC-UV-MS was analysed by Dr. Rolf Jansen (Department of Natural products, GBF) 
using a Hewlett Packard HPLC system (HP 1100) equipped with a DAD diode array UV 
detector. Separation was achieved with a Nucleosil 120-5 RP C18 column (125/2mm, 
Macherey-Nagel) coupled to a PE Sciex API 2000 LC/MS/MS system with an ACI device. 
The temperature used was 40°C. The active substances were identified using the masses 
and UV spectra in comparison with the following compound databases: 
 “Dictionary of Natural Products” database (Chapman and Hall/CRC) on CD rom, 
Antibase 2000 (VCH Wiley), and CrossFire Beilstein databases (MDL) (on-line). 
 
3.6. Spectrometric analyses and structure determination of the macrolactins 
 
3.6.1. Purification of the macrolactins using high performance liquid 
chromatography (HPLC) and LH-20 chromatography 
MeOH extracts and fractions were analysed by RP-HPLC using a Hewlett Packard 1090 
Series II HPLC system equipped with a gradient pump system, an UV diode array detector 
at 220-600 nm and an external light scattering detector (PL ELS-1000; Polymer 
Laboratories); Separation was achieved with a Nucleosil 100-5 C18 column (125/2 mm, 
Macherey-Nagel); the used solvents were A: 0.5 % acetic acid/H20 and solvent B: 0.5 % 
acetic acid/MeOH; and the following gradient was used at a flow rate of 0.3 ml/min: 52 % 
B 0 min; 60 % B 24 min; 100 % B 26 min; 100 % B 31min; 52 % B 32 min; 52 % B 35 
min; 3 µl of MeOH extract were injected. 
The macrolactins were separated by preparative RP-HPLC, using a Nucleosil column 100-
7 C18 (250/21mm, Macherey-Nagel); The solvents used were A: 0.5 % acetic acid/MeOH 
51 % and B: 0.5 % acetic acid/MeOH 56 %. 100 % A 0 min; 100 % B 60 min; 100 % B 35 
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min; flow rate 20 ml/min; the amount of extract injected was 40-60 mg of extract in 0.2 ml 
MeOH; UV detection at 280 nm. 
Each macrolactin was further purified by LH-20 chromatography, using a glass column 
760/25 mm; the solvent used was MeOH/dichloromethane (1:1); flow rate 5 ml/min. 5-7 
mg of the compound was injected. 
 
3.6.2. HPLC- UV-MS and MS-MS analysis 
HPLC-UV-MS was performed in the Department of Structure Biology, GBF, with the 
same procedure as in numeral 3.5.4. MS data were obtained on a MAT 95 mass 
spectrometer in EI and DCI mode (Finnigan). 
 
3.6.3. Nuclear magnetic resonance (NMR) 
NMR analyses were performed in the Department of Structure Biology, GBF. For NMR 
spectroscopy the samples were dissolved in 99,95 % MeOH-d4, chloroform-d3 or 
dichloromethane-d2; the data were obtained with a WM-600 spectrometer (Bruker). 
 
3.6.4. Optical Rotation and UV spectrum 
Optical rotation and UV spectrum were measured in UV MeOH (Merck) on a Polarimeter 
MC 241 (Perkin Elmer) (d = 10 cm) and a UV-2102 PC UV-VIS Scanning 
Spectrophotometer (Shimadzu). 
 
3.7. Optimisation of secondary metabolite production 
 
The optimal medium and conditions of growth for secondary metabolite production was 
investigated. Media (appendix media used) were modified in order to establish the optimal 
 56
conditions for production of the active secondary metabolites or in some cases to recover 
the activity. Different compounds for promoting the production of secondary metabolites 
were also added (Mg+2, Zn+, Mn+2, Fe+, and DMSO) and their influence in the bacterial 
growth and production of the active substance was studied and particularly, with the 
Cooper media composition was modified in order to study the influence of each 
component (See results). The evaluation of the efficiency and diversity of secondary 
metabolite production was performed analysing the HPLC spectra of the obtained MeOH 
extract, produced biomass and antibacterial activities of the different MeOH extracts 
obtained from the same producer microorganism. Biomass production was determined by 
the dry weight technique. For this purpose 1.5 ml of the cultures were placed in pre 
weighed microtubes, centrifuged at 12000 rpm for 10 min. After discarding the 
supernatant, obtained pellets were dried under vacuum conditions for 24 h. Afterwards, the 
tubes were weighted again and the biomass was calculated from the weight difference. The 
amount of macrolactin in the MeOH extract obtained from the different media was 
measured by diffusion agar test using Staphylococcus. aureus as assay organism. 
Concentration of macrolactins was estimated from a calibration curve made using pure 
macrolactins. In addition, chromatograms of the MeOH extracts were obtained to assure 
that the increase of inhibition observed in the diffusion test was due to the increase of 
macrolactins production. 
 
3.8. Optimisation of macrolactin production 
 
3.8.1. Selection of optimal media for macrolactin production  
20 media with different composition were tested for production of macrolactins by B. 
subtilis. Studied medium were: Xgen, Bacillus pumilus medium (Bpm), EM, Cooper, 
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GEN, SMM, Landy, CA, St-1, St-3, MIC 10, KMA, KMB, F1, LB, TSYEM, Seed, M61, 
R2A and OM (See media appendix). The strain was grown in the different media using the 
already mentioned procedure (Numeral 3.3). Tested parameters biomass and macrolactins 
production were measure as in numeral 3.7. 
 
3.8.2. Addition of compounds for promoting secondary metabolite production 
 
After selecting the best media for macrolactin production (Numeral 3.8.1), it was modified 
by the addition of different compounds for promoting the production of secondary 
metabolites (Mg+2, Zn+, Mn+2, Fe+, and DMSO). The effect of such additions on the 
biomass and macrolactin production was studied as previously described (Numeral 3.8.1).  
 
3.8.3. Influence of the media composition in the production of macrolactins 
The influence of each component of the medium selected for macrolactin production 
(Numeral 3.8.1) on the bacterial growth and production of the active substance was 
analysed. Modifications to the standard medium are presented in results. The evaluation of 
the biomass and macrolactins production was analysed as mentioned above (Numeral 
3.7.3).  
 
3.8.4. Effect of pH in macrolactin production 
Once the optimal composition of the media was established, the effect of the pH on both 
biomass and antibiotic production was tested. The tested pH conditions were 5.0, 7.0, 9.0 
and 10.0. Biomass and antibiotic production was quantified as described above.  
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3.8.5. Macrolactin production during bacterial growth 
The macrolactins production on the optimised medium was monitored during 9 days of 
bacterial cultivation. For this purpose, 10 different parallel cultures were inoculated and 
cultured at the standard conditions (Numeral 3.3). Every day, one culture flask was 
withdrawn and a MeOH extract prepared from it. Biomass and macrolactin production 
were determined as above described (Numeral 3.8.3).  
 
3.9. Two-dimensional gel electrophoresis 
 
3.9.1. Sample preparation 
100 ml of MH broth were inoculated at 107 CFU/ml with overnight cultures of methicillin 
resistant Staphylococcus aureus (MRSA3) and incubated at 37°C for 16 h in presence of 4 
µg/ml of 7-O-m (sub-MIC). Flasks without antibiotic were used as controls. The cells were 
harvested by centrifugation at 12000 rpm and stored at –70°C. Cell material (10 mg wet 
weight) was resuspended in 1 ml of reswelling solution for electrofocusing (IEF) (7.4 M of 
urea, 2 M thiourea, 4 % CHAPS, 30 mM dithiotreitol, 20 mM Trizma base, protease 
inhibitor cocktail [one table of Mini(tm) Complete per 20 ml solution; Roche]). 
Afterwards, the suspension was sonicated 6 times for 30 s (1 s repeating duty cycle, 
Labsonic U; Braun). Protein concentrations were determined by the procedure of Bradford 
[58]. 
 
3.9.2. Electrophoresis 
Two-dimensional gel electrophoresis was carried out according to the method of Görg 
[59]. About 300 µg of protein was applied to dry pH 3-10 IPG ReadyStrips (Bio-Rad). IEF 
was performed in a protean 150 kVh in total. The strips were then transferred to 1.5-mm-
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thick 12-15 % gradient SDS-polyacrylamide gels and developed overnight in the isoDalt 
system from Amersham Pharmacia Biotech. The gels were stained using colloidal 
Coomassie R-250, according to the method of Blum et al. [60]. Differential protein 
expression was visualized with the Z3 image analysis software (Compugen; 
http://www.2dgels.com). Protein spots of interest were excised and the samples prepared 
for MALDI-TOF according to Wissing et al [61]. 
 
 
 60
4. RESULTS 
 
The main purpose of this study was to discover novel biologically active secondary 
metabolites. Initially, it was necessary to obtain a great variety of strains from extreme 
environments around the world to access a wide diversity of microbes. The strains were 
evaluated for the production of secondary metabolites and subsequently, the ones 
producing secondary metabolites with interesting activities were further investigated to 
isolate and chemically characterise the substances responsible for this biological activity.  
 
4.1. Microorganisms producers of secondary metabolites with biological activities 
 
Bacteria, fungi, yeast, eukaryotic cells and insects were used as targets to evaluate the 
biological activity of 2048 MeOH extracts produced by the same number of bacterial 
strains isolated from different geographical areas. A total of 137 (6.7 %) strains (Figure 2), 
belonging to 25 genera (Figure 3), produced secondary metabolites with biological activity 
against one or more targets (Figure 4). 
Of the 137 microbial active extracts, 81 (59.1 %) showed antibacterial activity. Among 
them, 27 showed activity only against bacteria, 44 against bacteria and fungi/yeast, 12 
against bacteria and insects, and 16 showed antibacterial and cytotoxic activities. Antiyeast 
and antifungal activities were detected in 79 from the active 137 MeOH extracts (57.6 %). 
Among them, 67 extracts were active only against fungi, 10 against both targets and 2 were 
active exclusively against yeast. However, it is important to mention that from the 
originally 79 strains producing antifungal and antiyeast compounds, 74 of them either lost 
the ability to produce active secondary metabolites after the storage (low stability) or 
produced very low amount of active compounds. Therefore, only 5 antifungal and antiyeast 
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MeOH extracts were further analysed for chemical identification. 
From the 2048 MeOH extracts, 1536 were tested for cytotoxicity and cell proliferation 
effects on eukariotic cells (HeLa and L929). A total of 120 extracts (7.8%) were active by 
either affecting morphology and cell proliferation (71 extracts) or cytotoxic effect (49 
extracts). On the basis of these cytotoxic results, a group of 80 active extracts were 
selected for testing their activity against 4 different insect targets. A strong insecticidal 
activity against Anopheles albimanus and Musca domestica was detected with 28 extracts 
(35 %). Specifically, 20 extracts showed larvicidal activity against first instar larvae of A. 
albimanus and 9 against M. domestica. Noteworthy, when mortality of M. domestica larvae 
was not observed, retardation of the larval development and/or absence of adult emergency 
were frequently observed. Finally, non of the extracts showed activity against the other 
insect targets (Spodoptera frugiperda and Tenebrio molitor). 
The tested microbial extracts were actually a mixture of secondary metabolites. However, 
our aim was to isolate and identify the specific compounds conferring this biological 
activity. Therefore, the extracts with high biological activities against the different target 
microorganisms were further analysed. 
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Figure 2.  Phylogenetic relationships of the environmental isolates producing active 
secondary metabolites. 
 
 
 
 
 
The isolates producing active secondary metabolites were identified using 16S rRNA 
sequence analysis. 
The score bar represents 1 nucleotide substitution per 100 nucleotides.
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Figure 3.  Taxonomical classification of the 137 strains producing active secondary metabolites. 
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* Different genera represented by only 1 microorganism/each 
** Comparative 16S rRNA sequence analysis of these strains was related to uncultivated bacteria 
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Figure 4.  Synopsis of the screening for active secondary metabolites and biological activities of microbial extracts obtained during the study.  
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4.2. Optimisation of secondary metabolite production in strains showing low 
stability 
 
A total of 81 strains produced antibacterial activity after their isolation. However, 31 
strains lost the capacity of producing antibacterial compounds when a second MeOH 
extract was prepared from the stored glycerol stock. The fact that some strains lose the 
capacity of producing secondary metabolites with antimicrobial activity after already short 
storage periods is not unusual, since, it have been reported that most of the microbial 
strains are active producers of secondary metabolites only when they are freshly isolated 
[5]. The fact that the strains lost the capacity to produce active secondary metabolites can 
be attributed to unfulfilled nutritional needs or opposite, appropriate cultivation conditions 
which thus do not stress the producer strain which is required for secondary metabolite 
production [24.]. To recover the capacity of production of active substances a series of 
media used for secondary metabolite production were tested. Media for each microbial 
producer were selected after an intensive literature search and are summarised in Table 5. 
The evaluation of the stability of secondary metabolite production was performed 
comparing the biological activities of the different MeOH extracts obtained after 
cultivation in the different media. Most of the bacterial strains grew in at least 2 of the 
tested media. However, regaining the capacity to produce biologically active compounds 
was only achieved in 17 of the 31 tested strains. Therefore, it is clear that optimal growth 
can not be correlated with production of active secondary metabolites. Interestingly, with 
B. pumilus (strains MIK-SM 1014 and 2329) growth of the strain and production of the 
active compounds in the different media followed different patterns, even when both 
isolates belong to the same specie. Similar results were observed with the strains MIK-SM 
1242, 1244 and 2249 of B. laterosporus. As it can be concluded, optimal conditions for 
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secondary metabolite production seems to be strain related and not even related to strains 
belonging to the same genus or specie (Table 5).  
 
Table 5.  Optimisation of secondary metabolite production in strains showing low 
stability: effect of cultivation media in antimicrobial activity obtained. 
MIK-SM 
number 
Microorganisms Media Microbial 
Growth 
Antimicrobial 
Activity 
 
1225  Deleya pacifica M61 
ME 
M284 
M109 
EM 
LB 
Cooper 
PDB 
DSM 
OMLP 
Landy 
Xgen 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
2160 Bacillus thuringiensis OM 
GEN 
Xgen 
Bpm 
Cooper 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
380 Bacillus pseudofirmus M 61 
SMM 
Landy 
Xgen 
Cooper/Mn 
ANA 
+ 
- 
- 
- 
+ 
+ 
+ 
 
 
 
- 
- 
382 Bacillus agaradhaerens M61 
ANA 
Landy 
Xgen 
Cooper/Mn 
+ 
+ 
- 
- 
- 
+ 
- 
1014 Bacillus pumilus EM 
Cooper 
OMLP 
DSM 
Landy 
Xgen 
Bpm 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
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Continued Table 5. 
MIK-SM 
number 
Microorganisms Media Microbial 
Growth 
Antimicrobial 
Activity 
 
2329 Bacillus pumilus R2A 
Bpm 
Landy 
Xgen 
Cooper/Mn 
+ 
- 
+ 
+ 
+/- 
+ 
 
- 
+ 
- 
1223 Bacillus subtilis M61 
XGen 
Landy 
DSM 
Cooper/Mn 
NBG 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
1237 Bacillus sp. M61 
Cooper 
EM 
+ 
+ 
+ 
+ 
+ 
- 
1241 Bacillus lentus M61 
CA 
Landy 
Xgen 
Cooper/Mn 
Cooper 
+ 
+ 
- 
+ 
- 
+ 
+ 
- 
 
- 
 
+ 
1242 Bacillus laterosporus M61 
Cooper 
Xgen 
Bpm 
OM 
Seed 
Medium 
OMLP 
EM 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
+ 
- 
- 
+ 
1244 Bacillus laterosporus M61 
Cooper 
EM 
+ 
+ 
+ 
+ 
+ 
- 
2249 Bacillus laterosporus R2A 
BLPM  
Cooper 
Cooper/Mn 
Cooper/Mg 
Cooper/Fe 
+ 
+ 
- 
- 
- 
+ 
+ 
- 
 
 
 
- 
1229 Paenibacillus sp. EM  
Xgen 
Cooper 
TSB 
+ 
+ 
+ 
+ 
+ 
- 
+ 
- 
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Continued Table 5. 
MIK-SM 
number 
Microorganisms Media Microbial 
Growth 
Antimicrobial 
Activity 
 
1230 Paenibacillus sp. EM 
Xgen 
CooperMn 
TSB 
MSAM 
Bpm 
Landy 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
1473 Paenibacillus burgundia EM 
Xgen 
Cooper/Mn 
TSB 
MSAM 
Bpm 
BHI 
+ 
+ 
+ 
+ 
- 
+ 
- 
+ 
- 
- 
- 
- 
+ 
- 
2158 Streptomyces sp. OM 
Strept 1 
Strept 2 
Strept 3 
Cooper 
+ 
- 
- 
+/- 
+ 
+ 
 
 
- 
+ 
2387 Streptomyces nodusus OM 
Strept 1 
Strept 3 
Strept 4 
Strept 6 
+ 
+/- 
+ 
+ 
+ 
+ 
+ 
+ 
- 
+ 
2163 Streptomyces sp. OM 
Cooper 
+ 
+ 
+ 
+ 
2375 Micromonospora floridensis OM 
Mic 1 
Mic 10 
Mic 15 
PM-5 
+ 
+ 
+/- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
801 Methylobacter sp. R2A 
Methylobact
er 
CA 
Mineral M. 
Colby 
Methyl Thio 
+ 
+ 
- 
- 
+ 
+ 
+ 
- 
 
 
- 
- 
147 Alcaligenes eutrophus EM 
CooperMn 
Alc 1 
Alc 2 
+ 
+ 
+/- 
+ 
+ 
- 
- 
- 
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Continued Table 5. 
MIK-SM 
number 
Microorganisms Media Microbial 
Growth 
Antimicrobial 
Activity 
 
195 Alcaligenes sp. EM  
Alc 1 
Alc 2 
Cooper/Mn 
+ 
- 
+ 
+ 
+ 
- 
- 
- 
307 Pseudomonas fluorescens R2A 
KMB 
KMA 
M M 
YSE 
CooperZn/Fe
F1 M 
F2 M 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
+ 
2271 Burkholderia sp. R2A  
NBG 
LB 
PDB 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
707 Klebsiella pneumonia EM 
M-9 
TSB 
BHI 
Cooper/Mn 
+ 
- 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
743 Klebsiella planticola EM 
M-9 
TSB 
BHI 
Cooper/Mn 
+ 
- 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
931 Arthrobacter agilis R2A 
Veg M 
EM 
Cooper/Mn 
M 53 
PDB 
Production  
GEN 
Vegetative 
F2 
TSYEM 
YSE 
Vegetative 2 
GYM 
YEG 
+ 
+ 
+ 
- 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
+ 
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Continued Table 5. 
MIK-SM 
number 
Microorganisms Media Microbial 
Growth 
Antimicrobial 
Activity 
 
991 Arthrobacter sp. EM 
Vegetative 
Cooper/Mn 
M 53 
+ 
+ 
- 
+ 
+ 
- 
- 
- 
1376 Arthrobacter sp.  EM 
Vegetative 
Cooper/Mn 
M 53 
+ 
+ 
- 
+ 
+ 
- 
- 
- 
1387 Arthrobacter sp. EM 
Vegetative 
Cooper/Mn 
M 53 
+ 
+ 
- 
+ 
+ 
- 
- 
- 
1232 Rhodococcus erythropolis EM 
M 53 
CA 
M M 
GYM 
+ 
+ 
+ 
- 
+ 
+ 
- 
- 
- 
- 
In bold are the media used for the production of the first extract and in which after storage 
of the strain no active secondary metabolite production was observed. 
+ Optimal growth of the strain or antimicrobial activity in the corresponding media. 
- Absence of growth of the strain or not antimicrobial activity in the corresponding media. 
+/- Suboptimal growth of the strain in the corresponding media. 
 
4.3. Analysis of secondary metabolite production in a Bacillus laterosporus strain 
 
A standard procedure was established to optimise secondary metabolite production and 
subsequently, to identify the active compounds. This procedure, applied to several strains, 
will be illustrated with one of the most interesting strains, B. laterosporus MIK-SM 1242. 
The strain was isolated from Magadi Lake in Kenya and identified as B. laterosporus by 
16S rRNA sequence analysis. The first extract, obtained by cultivating the strain in M61, 
showed interesting activities against multiresistant bacterial strains (methicillin resistant S. 
aureus and vancomycin resistant enterococci strains), fungi and yeast. After a second 
extract was prepared in the same medium and at same cultivation conditions, none of the 
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above mentioned activities were observed, indicating that the strain lost the capacity for 
producing corresponding secondary metabolites. For recovery this capacity eight different 
media were tested: Cooper, Xgen, B. pumilus medium, M61, OM, EM, OMLP and seed 
medium. The strain recovered the ability to produce antimicrobial secondary metabolites in 
4 of the tested media (Figure 5). In some cases even antimicrobial activity not found in the 
first extract was induced by the new media. Most probably, the new media allowed other 
biosynthetic pathways thus production of other secondary metabolites not originally 
produced. A direct comparison of the effect of the cultivation media on the activity of 
whole MeOH extracts is a complicated task, due to their possibly different chemical 
composition. Finally, it was decided to use Cooper medium because when used for the 
cultivation of B. laterosporus strain, the obtained MeOH extract had an activity 
comparable to the one of the extracts obtained in other media and in addition presented the 
broadest antibacterial activity. 
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Figure 5.  Antibacterial activity of the MeOH extracts produced by Bacillus laterosporus 
in different media. 
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Activity: antibacterial activity was tested in a diffusion agar assay (mm of inhibition). 
 
Remarkably, in Cooper medium, an antibacterial peptide with activity against vancomycin 
resistant strains was produced by B. laterosporus. Further studies were performed in order 
to increase the production of this antibacterial peptide in order to allow its chemical 
characterization. For this purpose, Mg+2, Zn+, Mn+2, Fe+ and DMSO were added to the 
Cooper media (Table 6). 
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Table 6.  Compounds used for promoting secondary metabolite production 
 
Compound Product Final Concentration*  
Mn+2 MnSO4. 5H2O 0.004 % 
Zn+ ZnCl2 0.01 % 
Mg+2 MgSO4 0.05 % 
Fe+ FeSO4 0.01 % 
DMSO DMSO 3 % 
 DMSO: Dimethyl sulphoxide 
 *Final concentration used in the media culture 
 
Interestingly, the addition of Zn+ acted as a repressor of antimicrobial secondary 
metabolite production. Contrary, an increment of the activity was observed when Mn+2 was 
added to Cooper medium (Figure 6). Moreover, the addition of Mn+2 induced the 
production of secondary metabolites with activity against P. aeruginosa, not produced in 
the not supplemented Cooper medium. This activity was previously only observed in the 
MeOH extract obtained when the B. laterosporus strain was cultivated in M61 medium 
directly after the strain isolation. Finally, different concentrations of Mn+2 were tested 
(0.002, 0.004 and 0.008 %) but no significant differences were observed in the 
antibacterial activity of the obtained extracts. Further secondary metabolite productions 
were done by cultivating the strain in Cooper media with 0.004 % of Mn+2.  
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 Figure 6.  Antibacterial activity of the MeOH extracts produced by Bacillus laterosporus 
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O
strain, the composition of the Cooper/ medium was modified in order to study the 
influence of each component on the antibacterial properties of the extract obtained after 
cultivation of B. laterosporus strain (Table 7).  
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 Table 7.  Modifications in Cooper medium composition in order to increase the 
antibacterial activity. 
  KH2PO4 
(g/l) (g/l) (g/l)  
MgSO4 CaCl2  
(g/l) (g/l)  
Glucose Mn+2 
%  %  
4.1* 5.7 4 0.1 8x10 3
C 1.5  5.7 4 0.1 8x10-4 1 0.004 
C1 1.5  5.7 4 0.1 4x10-4 1 0.004 
C2 1.5  5.7 4 0.1 1.6x10-3 1 0.004 
C3 1.5 5.7 4 0.05 8x10-4 1 0.004 
C4 1.5 5.7 4 0.2 8x10-4 1 0.004 
C5 1.5 5.7 2  0.1 8x10-4 1 0.004 
C6 1.5 5.7 6 0.1 8x10-4 1 0.004 
C7 1.5 3  4 0.1 8x10-4 1 0.004 
C8 1.5 8.5  4 0.1 8x10-4 1 0.004 
O4 
Na2HPO4NH4NO3
Cooper       -4 + 0.004 
*4.1 g were the standard amount of KH2P added to Cooper medium. In previous studies 
was observed that the same antibacterial activity was obtained with 1.5 g further reductions 
tibacterial activity was obtained with 1 % further reductions 
dium with 1 % glucose. 
he performed modifications affected the antibacterial activity of the produced MeOH 
resulted in loss of activity. 
+3 % was the standard amount of glucose added to Cooper media. In previous studies was 
observed that the same an
resulted in loss of activity.  
C: unmodified Cooper medium with 1 % glucose. 
C1-C8: modified cooper me
 
T
extracts (Figure 7). However, a clear conclusion of the role of each component could not 
be withdrawn. Again, most probably, the metabolism of the B. laterosporus strain is 
affected by the different media composition and thus different secondary metabolites are 
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produced. However, by applying MeOH extracts on diffusion agar assays, the effect of 
media modifications on the overproduction of specific compounds found in the control 
medium or the production of a new compound can not be clarified due to the fact that the 
active compounds contained in the MeOH extracts act showing a synergistic effect.  
Several of the extracts obtained by cultivating the B. laterosporus strain in modified 
Cooper medium were used for isolation and characterisation of active compounds. For 
instance, from the extract obtained with C8,which had the highest activity against 
Pseudomonas aeruginosa, Amicoumacin B, was isolated. This single compound was 
responsible for the activity against this strain. Additionally, from the extract obtained with 
medium C4 an antibacterial peptide with activity against multiresistant bacteria was 
detected. However, the amount of produced peptide was not enough to allow its 
identification. 
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Figure 7.  Antibacterial activity of the MeOH extracts produced by Bacillus laterosporus 
Control: unmodified Cooper medium/ Mn+2. 
in Cooper medium/Mn+2 with different composition. 
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F
screening, 61 demonstrated good stability of secondary metabolite production. The 
antibacterial activity of these extracts against the different targets reference and clinical 
isolates was determined by both the microdilution and agar diffusion tests. In this form, 
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MeOH extracts with higher antimicrobial activity were selected for further studies. A 
highly active extract was considered when it showed more than 20 mm of inhibition of 
target strains in the agar diffusion test and showed activity until dilution 1/512 in the liquid 
test. A total of 29 MeOH extracts complied with the latter characteristics and were selected 
for further chemical characterisation. Specifically, 15 MeOH extracts were active against 
MRSA, 12 against VRE, 11 against gram negative strains and all against S. aureus,.  
 
4.5. Isolation and chemical identification of the active compounds contained in the 
ifferent methodologies were tested to find the most appropriate strategy to achieve rapid 
microbial extracts 
 
D
and efficiently the identification of the active substances contained in the different MeOH 
extracts produced during this study. For instance, TLC was used as a method for 
simultaneous evaluation of antimicrobial activity and subsequent isolation of the active 
substance. However, only few active compounds were isolated for identification using this 
methodology. Interestingly, TLC was also used to compare the pattern of activity of the 
producers that belong to the same genus. The strains producing the same active compounds 
(same TLC pattern of activities) were: two Bacillus pumilus (MIK-SM 977 and 988), two 
Bacillus subtilis (MIK-SM 1236 and 1238), three Bacillus laterosporus (MIK-SM 1242, 
1243 and 1244) and two Rhodococcus sp. (MIK-SM 138 and 139) (Table 8). In addition, 
this procedure was useful for the determination of the appropriate solvent mixtures for the 
elution of the active compounds using liquid chromatography in silica columns. The latter 
mentioned was a tentative approach for the isolation and purification of the active 
substances. However, did not allow an optimum separation of the active compounds 
contained in the MeOH extract and further HPLC purifications were necessary. Therefore, 
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the use of chromatography in silica columns as a method for isolation of active compounds 
for chemical identification was discarded. 
 
HPLC was the most successful strategy used for separation of the active compounds for 
identification purposes. Later, this was the routine approach used for the analysis of the 
active MeOH extracts. Indeed, a correlation between the biological activities and a zone in 
the chromatogram was directly performed in order to identify the corresponding active 
peak and determine its UV spectrum. A Further HPLC-UV-MS analysis allowed the 
determination of the molecular weight (MW) of the active compound. Finally, by means of 
a database comparison of obtained data (UV and MW) with those of known molecules, 
allows the prediction of the possible structure of the active substance. When not match 
with in the databases was found, further purification and NMR analysis were required in 
order to confirm the presence of a new molecule and elucidate its structure. Most of the 
compounds obtained in this study were characterised using this methodology (Table 8). 
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 Table 8.  Chemical identification of the antimicrobial compounds contained in MeOH 
extracts produced by 17 environmental isolates. 
MIK-SM 
number 
Producer Antimicrobial 
Activity 
Recognised structures 
1 Aeromicrobium 
erythreum 
S. aureus Peptides 
138=139 Rhodococcus sp. S. aureus Aromatic peptide 
2580=2579 Burkholderia sp. S. aureus 
MRSA 2 and 3
VRE 
S. pombe 
B. cinerea 
Quinol derivatives: 
2-Heptyl-4-quinolinone 
2-Heptenyl-3-methyl-4-quinolinone 
2-(2-nonenyl)-3-methyl-4-quinolinol 
Polyenes/ines 
2271 Bacillus sp. S. aureus 
MRSA 2 and 3
VRE 
P. aeruginosa 
E. coli 
Amicoumacin B 
Amicoumacin C 
Bacillaene 
969 Bacillus thuringiensis S. aureus 
MRSA 2 and 3
Peptides 
977=988 Bacillus pumilus S. aureus 
MRSA 2 and 3
P. digitatum 
R. oryzae 
Amicoumacin A  
Amicoumacin C  
Amicoumacin variant (mw=435) 
Unknown (mw=670) 
 
2329 Bacillus pumilus S. aureus 
MRSA 2 and 3
Amicoumacin A  
4 polar variants of Amicoumcin A 
1014 Bacillus pumilus S. aureus 
MRSA 2 and 3
VRAR 
P. aeruginosa 
E. coli 
F. fujikuroi 
R. oryzae 
Amicoumacin A 
Amicoumacin B 
Bacillaene 
Peptide: Surfactin or Pumiladicin B 
 
2584=2587 Bacillus subtilis S. aureus 
MRSA 2 and 3
VRE 
P. aeruginosa 
E. coli 
B. cepacia 
S. pombe 
B. cinerea 
P.digitatum 
F. fujikuroi 
Difficidine 
Oxydifficidine 
Bacillaene 
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Continued Table 8. 
 
MIK-SM 
number 
Producer Antimicrobial 
Activity 
Recognised structures 
234 Bacillus subtilis S. aureus 
MRSA 2 and 3
VRAR 
P. aeruginosa 
E. coli 
All tested fungi
Bacillomycin 
1236=1238 Bacillus subtilis S. aureus 
MRSA 2 and 3
F. fujikuroi 
Peptides with molecular mass above 
limit 1800. 
1242=1243= 
1244 
Bacillus laterosporus S. aureus 
VRE 
P. aeruginosa 
B. cepacia 
P. anomala 
M. pulcherrina
Bogorol A 
Bogorol C 
Bacillaene 
Lipopeptides and peptides 
Amicoumacin B 
 
2198a Bacillus ehimensis 
 
S. aureus 
MRSA 2 and 3
VRAR 
P. aeruginosa 
Tetraene and polyene compounds. 
2555 Bacillus niacini 
 
S. aureus 
VRE 
C. albicans 
C. glabrata 
C. anomala 
Moenomycin-B2 or Moenomycin-
A12 
Moenomycin A 
2586 Bacillus subtilis S. aureus 
MRSA 3 
VRE 
P. aeruginosa 
B. cepacia 
B. cinerea 
F. fujikuroi 
C. krusei 
C. tropicalis 
Unknown macrolactin  
Macrolactin A 
7-O-Succinylmacrolactin A or F 
Bacillomycin D2 and D1 or D3 
Oxydifficidin and Difficidin  
Surfactins 
Baccillomycin L1, L2 or L3 and L4 
or L5 
2162 Streptomyces 
panayensis 
P. digitatum 
P. anomala 
F. fujikuroi 
M. pulcherrina
 
Pentaenes (3) 
Fungichromin (Lagosin) 
Elizabethin (Isolagosin) 
Filipin II 
Filipin III 
Filipin IV 
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Continued Table 8. 
MIK-SM 
number 
Producer Antimicrobial 
Activity 
Recognised structures 
2198 Streptomyces sp. 
 
S. aureus 
MRSA 2 and 3
VRAR 
P. aeruginosa 
C. albicans 
C. glabrata 
C. anomala 
C. tropicalis 
P. anomala 
Actinomycin K1c 
Actinomycin X0d/X0Β 
Pentaenes 
MRSA: methicillin resistant Staphylococcus aureus 
VRAR: vancomycin resistant-ampicillin resistant enterococci 
VRE: vancomycin resitant enterococci 
 
Only 17 from the 29 MeOH extracts with high antimicrobial activity were successfully 
chemically characterised. The remaining extracts were not efficiently characterised 
because either meagre concentration of active substance or an inefficient separation of the 
active compound, peak overlapping, with the standard chromatography method. No further 
separation was attempted with improved HPLC or other separation methods. In addition, 
most of the antibacterials identified as peptides were not further characterised because their 
chemical properties exceed the limit of the available equipment (molecular masses above 
1800), active peptide did not show an UV spectrum or insufficient amount of the active 
peptide was obtained. In order to circumvent the latter problem, media modifications were 
attempted to increase production of active peptides but not significant improvements were 
obtained. 
In conclusion, over 50 compounds were identified from the different MeOH extracts. 
However, only one compound was recognised as a possible novel molecule. Indeed, the 
UV data indicated that this compound was a macrolactin but its MW did not correlate with 
any of the already known macrolactins. 
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4.6. The Bacillus subtilis strain producer of a new antimicrobial macrolactin 
compound 
 
The strain Bacillus subtilis MIK-SM 2586 produced 3 macrolactins and several other 
antimicrobial compounds. One of the macrolactins was identified as a new macrolactin 
according to its UV and MS data (Table 8). The strain was isolated from a soil sample 
obtained from a farmyard at Takalar, South Sulawesi Province, Indonesia on April 2000. 
This strain was phenotypic and biochemically characterized with the API 20E and 50CH 
kits (Biomerieux, France). The 16S rRNA sequence homology searches in the FASTA 
system corroborated the identification of the strain. The colony was opaque, ondulating, 
roughly edged and milky white. The strain was a gram-positive endospore (d. 0.2 µm) 
forming rod (0.5-1 x 1-3 µm) and it was motile with flagella. Biochemically, the B. subtilis 
strain was positive for oxidase, ornithine, mannitol, VP, citrate, TDA and hydrolysis of 
starch tests. Additionally, it was negative for nitrate, lysine, H2S production, glucose, 
xylose, ONPG, indole and ureasa tests. The producer B. subtilis strain was deposited in the 
DSMZ under the accession number DSM 16696. 
 
4.7. Production, extraction and purification of macrolactin compounds produced by 
Bacillus subtilis 
 
Cultures of the producer B. subtilis strain were grown in OM medium for 7 days at 30°C 
and a MeOH extract was prepared by the standard methodology previously described. The 
different compounds present in the MeOH extract were separated by RP-HPLC. A total of 
60 fractions were obtained, which were tested for antimicrobial activity by the agar 
diffusion assay. The strain produced around 10 different antibacterial compounds, which – 
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according to UV and MS data − were identified as bacillomycins, difficidins, 
oxydifficidins, aromatic lipopeptides, macrolactin type compounds; and among the 
macrolactins, a not yet reported compound (Table 8). The retention times of macrolactins 
were 13.9, 15.4 and 17.6 min, for compounds I, II and III, respectively. Compound II was 
the uncharacterised macrolactin (Figure 8). Efforts were concentrated in the production of 
enough amount of the three macrolactins required for the structural analysis and 
determination. A MeOH extract was produced from 4 L culture medium and the 
macrolactins separated by preparative HPLC. The fractions containing the three 
macrolactins were further purified by LH-20 chromatography. The yields from 4 L culture 
medium were 4-6 mg, 5-7 mg and 6-8 mg of compounds I, II and III, respectively. 
 
Figure 8.  HPLC chromatogram of a MeOH extract containing the macrolactin 
compounds.  
I II III 
 
 
4.8. Structural determination of the three macrolactin compounds produced by 
Bacillus subtilis  
 
The molecular ion m/z 402 and the UV absorptions at 227 and 261 nm enabled the 
identification of compound I as macrolactin A or its 10E-isomer, macrolactin I. The latter 
was ruled out by its optical rotation of [α]22D = −138 compared to about −10 found for 
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macrolactin A (I). A direct comparison of the NMR data of I was difficult, because only 
1H-NMR data in benzene-d6 and 13C-NMR data in pyridine-d5 are available in the 
literature. The 1H- and 13C-NMR data of the well resolved spectra of macrolactin A in 
MeOH-d4 are given in Table 9. The signals were identified by 1H,1H-COSY and 1H,13C-
HMBQ spectra.  
 
Chemical properties of Macrolactin A (I) produced by B. subtilis: C24H35O5, M = 
402.53, UV (MeOH): λmax (lg ε) = 227 (4.537), 261 (4.146) [Lit.: 227 (4.691), 261 
(4.272)]. [α]22D = − 10.7 (c = 0.68 in MeOH) [Lit.: − 9.6 (c = 1.86)]. MS: (−)-ESI (TOF): 
m/z (%) = 401.2 (38) [M−H]−, 437.2 (100) [M+Cl]−, 803.4 (63) [2M−H]−; (−)-DCI 
(isobutane): m/z (%) = 402 (100); (+)-DCI (isobutane): m/z (%) = 349 (56) [M+H−3 
H2O]+, 367 (100) ) [M+H−2 H2O]+, 385 (75) ) [M+H−H2O]+; EI (200 °C): m/z (%) = 255 
(100), 273 (72), 348 (18), 366 (68), 384 (60), 400 (5.9), 402 (2.5). NMR data are given in 
Table 9.  
 
Compound II was identified as a macrolactin A type compound from its identical UV 
spectrum. Mass spectrometry indicated the molecular mass of 488, which is 86 a.m.u 
higher than the mass observed for I. Corresponding to the elimination of one H2O from I, 
compound II showed the loss of malonic acid by a fragment-ion at m/z 383 in the (−)-ESI 
spectrum. The NMR data of II in MeOH-d6 were nearly identical to I. However, compared 
to I the 7-H signal was shifted about 1.2 ppm downfield as consequence of the acylation of 
7-O. The residue at 7-O was identified from the 1H- and 13C-NMR spectra by comparison 
with I. Because only one carboxy group was directly visible in the NMR spectra of II in 
MeOH-d4, a set of NMR spectra in dichloromethane-d2 clearly indicated the malonyl 
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residue by additional carboxy C signals at 166.33 and 169.15 ppm and a methylene C 
signal at 42.17 ppm, which was correlated to two H doublet signals at 3.51 and 3.40 ppm 
(J = 15.5 Hz). NMR data and chemical structure of the new compound are given in Table 
10, Figure 9 and Figure 10. 
13 13
1
 
Table 9.  NMR data of macrolactin A (I) in MeOH-d  ( H- and C). 1 134
m J C δC mH  δ  H
1 - - 1 168.02 s 
2 5.58  d  11.33  2 118.00 d 
3 6.67  t  11.71  3 144.96 d 
4 7.26  dddd  15.1, 11.4, 2, 1 4 130.26 d 
5 6.20  m  -  5 142.16 d 
6 2.45  m  -  6 42.84  t 
7 4.29  ddt  4.9, 1.2, 6.8  7 72.33  d 
8 5.79  dd  15.1, 6.0  8 137.55 d 
9 6.61  ddt 15.2, 11.0, 1.1 9 125.96 d 
10 6.15  t  11.14  10 131.39 d 
11 5.58  ddd  10.5, 8.6, 8.2  11 128.39 d 
12a 2.53  dddd 13.5, 8.2, 7.4, 0.8
12b 2.36  dddd  13.5, 7.7, 4.9, 1.1 12 36.50  t 
13 3.89  ddt 5.3, 5.1, 6.9  13 69.24  d 
14 1.65  m  -  14 43.92  t 
15 4.34  dt  6.3, 6.3 15 69.83  d 
16 5.60  dd 15.1, 6.5 16 135.23 d 
17 6.21  dd  15.5, 10.9  17 131.21 d 
18 6.09  dd  14.9, 10.4  18 131.72 d 
19 5.69  ddd  14.7, 7.2, 6.8  19 135.13 d 
20a 2.23  ddt  14.2, 7.1, 6.8 
20b 2.14  ddt  14.2, 6.4, 7.1  20 32.98  t 
21 1.54  m  -  21 25.65  T 
22a 1.68  m  -  
22b 1.61  m  -  22 36.01  T 
23 5.05  ddq  7.3, 4.5, 6.2 23 72.21  D
24 1.29  d  6.04  24 20.11  Q
- 
1H at 600 MHz; 13C at 150 MHz; multiplicity of carbon signals from DEPT and HMQC 
spectra.  
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Chemical properties of 7-O-malonyl macrolactin A (7-O-m) (II) produced by B. 
subtilis: C27H36O8, M = 488.57, UV (MeOH) (Figure 9): λmax (lg ε) = 227 (4.397), 230 
(sh), 260 (4.006). [α]22D = − 6.2 (c = 0.63 in MeOH). MS: (−)-ESI (TOF): ): m/z (%) = 
487.2 (100) [M−H]−, 443.2 (44) [M−H−CO2]−, 383.2 (27) [M−H−malonic acid]−; (Table 
10).  
 
Figure 9.  UV spectrum of 7-O-malonyl macrolactin A (II) in MeOH 
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 Table 10.  NMR-Data of 7-O-malonyl macrolactin A (II) in MeOH-d4 (1H- and 13C). 
H δH m J [Hz] C δC m 
1 - - - 1 167.94 s 
2 5.59  d  11.7  2 118.52 d 
3 6.67  t  11.3  3 144.50 d 
4 7.25  dd  14.7, 11.7  4 130.79 d 
5 6.15  dt  15.4, 7.2 5 140.51 d 
6 2.60  m  5.3 6 40.13  t 
7 5.50  ddd  6.0, 6.0, 6.0  7 74.72  d 
8 5.75  dd  15.3, 5.5  8 132.06 d 
9 6.71  dd  15.1, 11.3  9 128.09 d 
10 6.13  t  10.2  10 130.91 d 
11 5.63  dt 10.6, 8.4 11 129.78 d 
12a 2.63  m  -  
12b 2.33  ddd  13.0, 7.2, 5.5 12 36.39  t 
13 3.84  ddd 10.6, 6.0, 5.7 13 69.51  D 
14 1.66  m  -  14 43.84  T 
15 4.39  dt 6.3, 6.3 15 69.77  D 
16 5.60  dd  15.1, 6.4  16 135.32 D 
17 6.21  dd  15.1, 10.6  17 131.27 D 
18 6.10  dd  15.1, 10.6  18 131.78 D 
19 5.69  ddd  14.9, 7.0, 6.8 19 135.10 D 
20a 2.23  td  14.0, 6.8 
20b 2.15  td  14.4, 7.2 20 33.03  T 
21 1.54  m  -  21 25.81  T 
22a 1.70  m  -  
22b 1.62  m  -  22 36.08  T 
23 5.05  ddq  4.5, 7.1, 6.1  23 72.37  D 
24 1.30  d  6.0  24 20.14  Q 
1’ - - - 1’ 169.64 S 
2’ 2.90  m  - (br) 2’ 44.74  (a)
3’ - - - 3’ n.o.  
1H at 600 MHz; 13C at 150 MHz;  
(a) from HMQC NMR spectrum.  
n.o.= not observed due to signal broadening  
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Figure 10.  H-NMR spectrum and chemical structure of 7-O-malonyl macrolactin A (II) in dichloromethane-d2 (600 MHz) 
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Compound III was identified as 7-O-succinyl macrolactin A. The 1H NMR data of III in 
CDCl3 were found to be identical to those in literature [62]. 
 
Chemical properties of 7-O-succinyl macrolactin A (7-O-s) (III) produced by B. 
subtilis: C28H38O8, M = 502.60: UV (MeOH): λmax (lg ε) = 227 (4.596), 259 (4.192) [Lit.: 
229 (4.57), 261 (4.18)]. [α]22D = − 19.9 (c = 0.7 in MeOH) [Lit.: − 9.6 (c = 0.18 in 
MeOH)]. MS: (−)-ESI (TOF): m/z (%) = 501.28 (100) [M−H]−, 117.02 (12) [succinic 
acid−H]−; (−)-DCI (isobutane): m/z (%) = 502.7 (100), 484 (44), 402 (18), 384 (68), 366 
(26), 117 (20).  
In Figure 11 the chemical structures of the macrolactins produced by B. subtilis are 
compared. The difference between the three compounds is in the residue in C7. 
 
Figure 11.  Chemical structure of the macrolactins purified from the MeOH extract 
produced by Bacillus subtilis. 
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Macrolactin A   (I) R = H  
7-O- malonyl macrolactin A   (II) R = CO-CH2-COO  
7-O- succinyl macrolactin A   (III) R = CO-CH2-CH2-COOH 
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 4.9. Optimisation of macrolactin production by Bacillus subtilis strain  
 
The effect of some cultivations parameters (e.g. pH, media composition) on the 
macrolactin production by B. subtilis was studied. Activities of the obtained MeOH 
extracts were tested against several multiresistant strains by diffusion agar test. In addition, 
it was proved that Staphylococcus aureus was exclusively sensitive to the macrolactin 
fractions of the MeOH extracts. In this form, the inhibition zone obtained with the whole 
extract could be correlated specifically to the macrolactin activity. Moreover, calibration 
curves were done with purified macrolactins for quantitative purposes. Finally, 
chromatograms of each extract were always compared to ensure that the overall pattern did 
not vary considerably with the new conditions and that main changes were observed in the 
peaks corresponding to the macrolactins. Important is to mention that traces of compounds 
with chemical characteristics similar to those of the macrolactin, similar retention times, 
were often found. 
 
4.9.1. Media selection for macrolactin production  
A total of 20 different media were tested in order to find the conditions appropriate for 
macrolactin production. The tested media were selected containing different carbon and 
nitrogen sources as well as different trace elements, vitamins and amino acids. 
The B. subtilis strain grew in all tested media, but St-1, SMM, M61 and seed medium. 
Interestingly, in Bpm the strain was able to grow, however, the obtained extract was not 
active against the tested strains. In contrast, all other tested media which were able to 
support B. subtilis growth allowed also production of antibacterial secondary metabolites 
with activities against the bacterial target strains and specially against vancomycin 
resistant-ampicillin resistant enterococci (VRAR) (Figure 12). Of particular interest was 
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 the high antibacterial activity observed in the MeOH extracts produced in F2 and OM 
media which contrasted with the scarce biomass obtained. This independence of the 
biological activity and the produced biomass was frequently observed during the whole 
study. 
 
Figure 12.  Antibacterial activity of the MeOH extracts and biomass produced by Bacillus 
subtilis strain in different media. 
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MRSA: methicillin resistant Staphylococcus aureus 
VRAR: vancomycin resistant-ampicillin resistant enterococci 
Activity: antibacterial activity was tested in an agar diffusion assay (mm of inhibition). 
In the graphic are only included the media in which activity was detected. 
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 The macrolactin concentration of the produced extracts was deduced from the 
able 11.  Quantification of macrolactins production by Bacillus subtilis strain grown in 
Media Macrolactins µg /µl 
antimicrobial activity against S. aureus. Highest macrolactin production was observed in 
OM, F2 and Xgen media (Table 11). This result was confirmed by comparing the HPLC 
chromatograms of the extracts. Indeed, similar chromatogram patterns were obtained from 
the different media and only differences were found in the peaks corresponding to the 
macrolactins. For further studies OM medium was selected since traces of several 
compounds with chemical characteristics similar to the macrolactins, which interfered with 
the purification process, were kept at minimum. 
 
T
different media. 
Xgen 3.7 
EM 3.1 
Cooper 3.1 
GEN 3.1 
Landy 1.7 
CA 2.4 
St-3 3.1 
Mic-10 3.1 
KMA  1.7 
KMB 2.8 
F2 3.7 
LB 3.1 
TSYEM 3.1 
R2A 2.2 
OM 3.7 
 
.9.2. Addition of compounds for promoting macrolactin production  
 was attempted 
4
Optimisation of macrolactin production by Bacillus subtilis in OM medium
by modifying the media composition with the addition of the compounds for promoting 
secondary metabolite production reported in the literature [12, 63, 64]. However, these 
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 modifications did not have a positive effect on the activity of the obtained MeOH extracts 
(figure 13). In fact, in some cases media modifications negatively affected the antibacterial 
activity of the produced MeOH extracts. From the antibacterial activity against S. aureus, 
macrolactin concentration was calculated as 3.0±0.2 µg/µl in all tested media. 
Interestingly, some effects of the compounds tested for promoting secondary metabolite 
production were observed on the biomass. When Zn2+ was added to the medium, no 
growth of the strain was detected. In contrast, in the presence of Mn2+, the production of 
biomass increased significantly in comparison to the other media. For further studies OM 
medium without additives was retained as the production medium. 
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Figure 13.  Antibacterial activity of extracts and biomass produced by Bacillus subtilis in 
OM medium with addition of compounds for promoting secondary metabolite production. 
Control: OM medium without compounds for promoting secondary metabolite production 
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Concentrations: 0.05 % Mg+2 , 0.004 % Mn+2 , 0.01 % Zn+ , 0.01 % Fe+ and 3 %DMSO 
MRSA: methicillin resistant Staphylococcus aureus 
VRAR: vancomycin resistant-ampicillin resistant enterococci 
Activity: antibacterial activity was tested in an agar diffusion assay (mm of inhibition) 
Addition of Zn+ resulted in not growth 
 
4.9.3. Influence of the OM medium composition in the macrolactin production 
The influence of the different components of the OM medium on biomass, secondary 
metabolite and macrolactin production was evaluated. Modifications were made by either 
removing one component, increasing 5 fold concentration of one component (retaining all 
other components) or increasing the concentration of all the components (Table 12). 
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Table 12.  Modifications to the composition of OM medium. 
 
 OM Medium 
Solutions (ml/l):  Starch 
(g/l) 
Glucose
(g/l) 
Peptone
(g/l) 
Yeast extract
(g/l) A B C D 
C 1 1 1 1.5 10 10  1  1  
OM1 0 1 1 1.5 10 10 1 1 
OM2 5 1 1 1.5 10 10 1 1 
OM3 1 0 1 1.5 10 10 1 1 
OM4 1 5 1 1.5 10 10 1 1 
OM5 1 1 0 1.5 10 10 1 1 
OM6 1 1 5 1.5 10 10 1 1 
OM7 1 1 1 0 10 10 1 1 
OM8 1 1 1 7.5 10 10 1 1 
OM9 5 5 5 7.5 10 10 1 1 
OM10 1 1 1 1.5 10 0 1 1 
OM11 1 1 1 1.5 10 30 1 1 
OM12 1 1 1 1.5 10 10 0 1 
OM13 1 1 1 1.5 10 10 3 1 
OM14 1 1 1 1.5 10 10 1 0 
OM15 1 1 1 1.5 10 10 1 3 
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 Continued Table 12. 
 OM Medium 
Solutions (ml/l):  Starch 
(g/l) 
Glucose 
(g/l) 
Peptone 
(g/l) 
Yeast extract 
(g/l) A B C D 
OM16 1 1 1 1.5 10 0 0 0 
OM17 1 1 1 1.5 10 30 3 3 
 C: OM medium standard composition 
 OM1-17: OM medium with modified composition 
 Solutions A, B, C and D: see appendix media 
 Solution A buffer without variations (media pH) 
 
 
The biomass production was highly influenced by the cultivation media. Maximum 
biomass production was obtained in OM9 (Figure 14), where all the components, except 
the solutions, were increased. 
The effect of the medium composition in the biological activity of the macrolactins was 
evaluated determining: a) the antibacterial activity of the obtained extracts against target 
strains using agar diffusion tests (Figure 14) and b) quantification of the amount of 
macrolactin produced using calibration curves (Figure 15). Despite the great differences in 
media composition, all obtained MeOH extracts presented antibacterial activity. Similar to 
the biomass production, the antibacterial activity varied depending on the proportions of 
the reagents. Highest activity against the target strains was produced in OM9 medium 
(Figure 14). Concerning the macrolactin production, highest amounts were produced in 
OM2, OM9 and OM17 media (Figure 15). Interestingly, in OM2 medium the biomass 
production was low, however, high antibacterial activity and macrolactin production were 
obtained. Macrolactin production was the same in OM2, OM9 and OM17, but the extracts 
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 from cultures of OM2 and OM17 gave products with retention times similar to one of the 
macrolactins, which would complicate the purification process of the macrolactin, and thus 
these media were discarded. 
 
Figure 14.  Antibacterial activity of the MeOH extracts containing macrolactins and 
biomass produced by Bacillus subtilis in OM medium with different composition 
 
ontrol: OM medium with unmodified composition 
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Figure 15.  Quantification of Macrolactin production by the Bacillus subtilis grown in OM 
.9.4. Effect of medium pH in macrolactin production by Bacillus subtilis  
. subtilis strain cultivated in OM9 medium, was able to grow in a wide pH range, which is 
ined at pH 
medium with different composition 
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4
B
one of the Bacillus genus characteristics. Optimum biomass production was obta
7.0 and any deviation from this value considerably affected cell growth. Interestingly, the 
antibacterial activity against the target strains and also the macrolactin production were not 
correlated with the amount of produced biomass. Similar antibacterial activity (Figure 16) 
as well as macrolactin production (6.8 µg/µl) was obtained at the different pH conditions. 
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Figure 16.  Antibacterial activity of the MeOH extracts and biomass produced by Bacillus 
btilis in OM9 medium at different pH conditions. 
ctivity: antibacterial activity was tested in an agar diffusion assay (mm of inhibition).  
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T
extracts were monitored during 9 days of incubation. Cell growth and antibacterial
compounds production reached a maximum between 8-9 and 7-8 days respectively. In 
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 contrast, the macrolactin production reached the maximum after five days of cultivation 
(Table 13). Remarkably, most of the secondary metabolite production was achieved during 
the first day of cultivation (Figure 17). No degradation of macrolactins and other 
antibacterial compounds over the 9 production days was observed, due to the protection 
conferred by the adhesion of the metabolites to the amberlite resin XAD-16. 
 
Figure 17.  Antibacterial activity of the MeOH extracts and biomass produced by Bacillus 
btilis in OM9 medium during 9 days. 
ctivity: antibacterial activity was tested in an agar diffusion assay (mm of inhibition). 
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 able 13.  Quantification of macrolactins production by the Bacillus subtilis grown in OM9 
edium during 9 days 
T
m
Time (days)Macrolactins µg /µl 
1 3.2 
2 3.5 
3 3.5 
4 4.1 
5 4.3 
6 4.1 
7 4.3 
8 4.3 
9 4.3 
iva acr
 
In summary, B. subtilis cult tion conditions for m olactins production were found to be 
ptimal in OM9 medium at pH 7.0. In this conditions maximum macrolactin concentration 
unds  
fied by several chemical 
xtractions followed by preparative RP-HPLC and LH-20 chromatography (see materials 
o
was obtained after 5 days of cultivation. The latter was the standard procedure for 
producing macrolactin during the rest of the present study. 
 
4.10. Antimicrobial activities of the macrolactins compo
 
The three macrolactins produced by the B. subtilis strain were puri
e
and methods). The biological activity of each macrolactin was investigated against a broad 
spectrum of microorganisms including reference strains and clinical isolates, by means of 
agar diffusion assay. The new macrolactin (compound II = 7-O-malonyl macrolactin A) 
was the most active macrolactin compound produced by the B. subtilis strain. In the agar 
diffusion assay, a large zone of inhibition of bacterial growth was observed around the disc 
(Table 14). However, growth inhibition was not complete and little colonies could be 
detected inside the zone of compound activity. The higher inhibition values obtained with 
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 the MeOH extract were consequence of the additive effect of the three macrolactins and 
the other secondary metabolites with antibacterial activity produced by the strain (Table 
14). 7-O-malonyl macrolactin A (7-O-m) showed antimicrobial activity against a wide 
number of strains. The obtained antimicrobial activity was comparable or superior to that 
of erythromycin (Table 14). Remarkably, 7-O-m was able to inhibit the growth of 
methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci 
(VRE) clinical strains.  
 
Table 14.   In vitro activities of the macrolactins produced by Bacillus subtilis in 
omparison with the MeOH extract and commercial antibiotics. 
e (mm) 
c
 
 Inhibition zone siz
Strain MeOH
extract
a 
I 
macrolactin 
Ab 
II 
7-O-mb 
III 
7-O-sb 
ERYc VANd AMPe 
S. aureus DSM 1104 28 18  20 30 26 18 30
S. aureus 32 32  
MRSA2 0 24 0 
MRSA3 28 41 38 0 24 0 
RAS) 
 (VRAR)  
 SCV  
25 30 22 40 27 41 
24 27 
35 
40 37 
E. faecalis  18 0 25 12 25 24 32 
E. faecalis (V 15 0 15 0 0 0 35 
E. faecium 40 0 15 20 25 0 0 
B. cepacia 40 0 15 0 0 ND 0 
a10 µl/disc , b50 µg/dis 8 µg sc, d30 µg/disc and e10 µg/disc 
nl  targ  reference a linical s ins against which high activity 
nyl m lact A 
comycin-resistant Ampicillin-sensitive 
illin-resistant 
c, c7 /di
In table are shown o y the et nd c tra
was found 
7-O-m: 7-O-malo acro in 
7-O-s: 7-O-succinyl macrolactin A 
MRSA: Methicillin-resistant Staphylococcus aureus 
VRAS: Van
VRAR: Vancomycin-resistant Ampic
SCV: Small colony variant 
ND: not determined 
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 4.11. Minimal Inhibitory Concentrations of the 7-O-malonyl macrolactin A  
ins were 
etermined by the standard twofold serial MH broth microdilution method described by the 
served at concentrations of 4 and 
s, at concentrations of 7-O-m 
etween 0.06 and 32 µg/ml, encouraged us to further investigate the bacteriostatic activity 
 
Minimal inhibitory concentrations (MIC) of 7-O-m against the target stra
d
National Committee for Clinical Laboratory Standards (NCCLS) [54]. For many strains the 
MIC was not reached within the used concentration range (Table 15). However, very 
interestingly, the growth of some of these strains was affected already at relative low 
macrolactin concentration, to an extent that almost no turbidity was detected. For instance, 
the MIC of the 7-O-m for staphylococci were higher than 128 µg/ml, but a strong 
inhibition of the bacterial growth was observed already at concentrations of 1 and 4 µg/ml 
for the reference and for the MRSA strains respectively.  
A similar effect was observed against all the enterococci strains. Indeed the MIC stands 
over 128 µg/ml but substancial growth inhibition was ob
0.06 µg/ml for the Enterococcus faecalis reference strain and the vancomycin resistant – 
ampicillin resistant (VRAR) and vancomycin resistant – ampicillin sensible (VRAS) 
strains. Moreover, a similar action was observed with Burkholderia cepacia SCV at 
concentrations of 32 µg/ml, but not with the WT strain where the MIC value was higher of 
128 µg/ml. These concentrations, lower than MIC and where strong inhibition of the 
microbial growth was observed, were designated sub-MIC.  
 
The strong bacterial growth inhibition observed at sub-MIC
b
by studying the kinetics of growth at these concentrations. 
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 able 15.  MICs of the 7-O-malonyl macrolactin A and other agents against the target 
rains. 
7-O-malonyl macrolactin A 
 
T
st
 
Target strain MIC  
µg/ml  
Sub-MIC 
µg/ml 
VAN 
µg/ml 
AMP 
µg/ml 
ERY 
µg/ml 
GEN 
µg/ml 
MCZ 
µg/ml 
S. aureus >128 1 0.125 0.06 0.06 0.25 ND 
>128 4 
MRSA3 >128 4 1 64 0 128 ND 
E. faecali 128 4 2 0.5 2 32 ND 
VRAS en >128 0.0 >1 0.5 12 64 ND 
VRAR ente >128 4 >1 >128 2 64 ND 
E. coli  >128 - 0 2 32 1 ND 
P. aeruginosa  >128 - 0 128 64 128 ND 
P. aerug >128 - 0 >1 128 2 ND 
P. aeruginosa S >128 - 0 >128 128 8 ND 
P. aeruginosa NM >128 - 0 >128 >128 64 ND 
S. maltophilia  >128 - 0 >128 128 16 ND 
B. cepacia WT >128 - 0 >128 >128 >12 ND 
B. cepacia SCV 128 32 0 128 128 >12 ND 
C. parapsilosis 128  - 0 N/D N/D N/D 2 
C. krusei 128 32 0 N/D N/D N/D 2 
C. albicans >128 - 0 N/D N/D N/D 2 
Sub-MIC:
observed 
 At these ntrations a strong inhibitory effect in the bacterial growth was 
rmined 
icillin r t Staph ococcus aureu
conce
ND: not dete
MRSA: meth esistan yl s 
MRSA2 2 0 0 128 ND 
s  
terococci 6 28 8 
rococci  28  
  
inosa WT 28  
CV   
  
 
8 
  8 
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 VRAS: vancomycin resistant-ampicillin sensitive enterococci 
VRAR: vancomycin resistant-ampicillin resistant enterococci 
owth at sub-MIC of the 7-O-malonyl macrolactin A  
lactin, growth 
urves of the target strains were performed at sub-MICs. Specifically, 7-O-m was tested at 
st 4-6 hours. The 
WT: wild type  
SCV: Small colony variants 
CF: Cystic fibrosis 
NM: Non mucoid 
 
4.12. Kinetics of gr
 
To further investigate the extent of the bacteriostatic effect of the new macro
c
sub-MIC and 4x sub-MIC values for the microorganisms in which it was detected. The 
growth curves obtained indicated that the new macrolactin reduced the number of viable 
cells of S. aureus reference strain during the first 4 hours of treatment (Figure 18A). 
Afterwards, bacterial growth was similar to that of the control but the bacterial 
concentration in the treated cultures remained 1 log10 lower than the control. Moreover, 7-
O-m slightly affected the growth rate of MRSA during the first hours of treatment, and 
after 4 h of treatment bacterial growth was almost completely inhibited. After 24 h 
treatment the viable counts of control and treated cultures showed differences of more than 
2 log10 (Figure 18B). After 4 h, 7-O-m inhibited the growth of the E. faecalis reference 
strain. Afterwards, the viable counts of the treated bacteria were significant lower than the 
control culture reaching a maximum difference of 1 log10 at the end of the treatment 
(Figure 19A). Similarly, for VRAR E. faecium strain, no important growth differences 
were observed during the first hours of 7-O-m treatment but afterwards, macrolactin 
treatment almost completely inhibited the bacterial growth (Figure 19B). 
Growth of Burkholderia cepacia SCV at sub-MIC was affected directly after starting the 
macrolactin treatment. In fact, little growth was observed during the fir
viable counts at the end of the treatment differed 1-1.5 log10 between control and treated 
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 cultures (Figure 20A). Lower activities were observed against Candida krusei, the only 
yeast affected by 7-O-m (Figure 20B), in which the viable counts of the treated bacteria 
were similar to the control values and only a slight difference was observed between sub-
MIC and 4x sub-MIC. 
Finally, a concentration-dependent effect was not observed with 7-O-m at 2 different sub-
MICs for each strain.  
Interestingly, the 7-O-m showed a more pronounced bacteriostatic effect on the growth of 
resistant gram positive pathogens, where the viable counts do not increase significantly 
during 24 hours. B. cepacia SCV, was the only gram negative strain affected by 7-O-m.  
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 Figure 18.  Growth curves of Staphylococcus aureus (A) and MRSA 3 (B) in the presence 
or not of 7-O-malonyl macrolactin A 
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The curve numbers refer to the 7-O-m concentration of the antibiotic in µg/ml and 
represent control (0), sub-MIC and 4x sub-MIC.  
MRSA 3: methicillin resistant Staphylococcus aureus 
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 Figure 19.  Growth curves of Enterococcus faecalis (A) and VRAR (B) in the presence or 
not of 7-O-malonyl macrolactin A  
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The curve numbers refer to the 7-O-m concentration of the antibiotic in µg/ml and 
represent control (0), sub-MIC and 4x sub-MIC.  
VRAR: vancomycin resistant-ampicillin resistant enterococci 
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 Figure 20.  Growth curves of Burkholderia cepacia SCV (A) and Candida krusei (B) in the 
presence or not of 7-O-malonyl macrolactin A  
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The curve numbers refer to the 7-O-m concentration of the antibiotic in µg/ml and 
represent control (0), sub-MIC and 4x sub-MIC.  
SCV: Small colony variants 
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 4.13. Post-Antibiotic effect measurements of the 7-O-malonyl macrolactin A  
 
Post-antibiotic effect (PAE) is a term used to describe suppression of bacterial growth that 
persist after brief exposure of organisms to antimicrobials. The “post-activities” of an 
antibiotic are not only inhibition of regrowth but also additional effects that include 
morphological and physiological changes including potential alterations of cellular 
functions and virulence factors. A prolonged PAE play a beneficial role because during the 
time that the bacterial pathogen remain inhibited as a result of PAE, it may be sensitive to 
the lethal effects of patient leukocytes. In addition, the PAE have a clinical impact on 
antimicrobial dosing regimens. For example, drugs with not PAEs may require more 
frequent administration than those that demonstrate PAE. The in vitro PAE of 7-O-m with 
VRAR E. faecium and MRSA 3 strain was examined to evaluate the extent of bacterial 
damage at sub-MIC. The PAE was tested after 1 h of exposure at 16 µg/ml of 7-O-m. The 
treated MRSA showed a PAE of 0.42 h and the VRAR E. faecium a PAE of 2.31 h, 
indicating that the compound was able to induce a strong damage particularly on 
enterococci cells even at sub-MICs. 
PAE values, were significantly longer with VRAR E. faecium than with MRSA 3. During 
the pre-PAE time, in which the cells were incubated in presence of the antibiotic, the 
bacteriostatic effect was confirmed, because no growth was detected at this stage.  
 
4.14. Morphology alterations in strains treated with sub-MIC of 7-O-malonyl 
macrolactin A  
 
In an attempt to investigated the observed bacteriostatic effect of 7-O-m on the target 
strains, morphological changes of treated bacteria were monitored by transmission electron 
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 microscopy (TEM). Growth in the presence of 7-O-m had a very marked effect on VRAR 
E. faecium (Figure 21), MRSA3 (Figure 22) and B. cepacia SCV (Figure 23) in 
comparison to untreated controls. Cell division and separation of daughter cells were 
severely disrupted because of incomplete formation of the septa. In VRAR E. faecium 
(Figure 21) initiation of several symmetric cell divisions can be observed in each cell 
without finalization of the preceding. Moreover, the rough surface of the control cells was 
not detected in the treated cells. Similar behaviour was observed with MRSA 3 (Figure 22) 
but, in this case, the invaginations representing initiation of cell division were not as 
symmetrical as in VRAR E. faecium. Finally, 7-O-m treatment of Burkholderia cepacia 
SCV (Figure 23) resulted in formation of atypical buds in the cell division site and changes 
in the morphology and dimension of the cells were also observed.  
To conclude, TEM observations revealed alterations in the cell division process and 
morphology of the three pathogens treated with 7-O-m . 
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 Figure 21.  Effects of 7-O-malonyl macrolactin A on the morphology of VRAR E. faecium 
clinical isolate.  
 
Control (a, b and c) and after 4 h of growth in the presence of 16µg/ml of 7-O-m (d, e and 
f). The division planes are indicated with large arrowheads. Abnormal division (arrow) and 
pseudomulticellular chains (white asterisk) with abnormal septa (small arrowheads) 
without apparent cell division are observed in treated enterococci. 
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 Figure 22.  Effects of 7-O-malonyl macrolactin A on the morphology of MRSA 3 clinical 
isolate.  
 
Control (a, b and c) and after 4 h of growth in the presence of 16µg/ml of 7-O-m (d, e and 
f). The division plane and cross wall are indicated with white arrowheads in the control 
cells (b and c). The division planes are indicated with big black arrowheads in the treated 
bacteria (e and f). Asymmetrical initiation of division is also observed in treated cells (little 
black arrowheads) in (e and f). 
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 Figure 23.  Effects of 7-O-malonyl macrolactin A on the morphology of Burkholderia 
cepacia SCV clinical isolate.  
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Control (a, b and c) and after 4 h of growth in the presence of 128µg/ml of 7-O-m (d, e and 
f). The division plane and cross wall are indicated with white arrowheads in the control 
cells (b and c). The division planes and atypical buds formation are indicated with big 
black arrowheads in the treated bacteria (e and f). Abnormal size of the cells was observed 
in treated cells (black arrow in d).  
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 4.15. Eukaryotic cytotoxicity of the 7-O-malonyl macrolactin A  
 
The eukaryotic cytotoxicity assay is used for evaluating the potential toxic properties of the 
bioactive compounds. Cytotoxicity includes changes in the normal cellular proliferation or 
morphology. A concern in the development of therapeutic agents is the cytotoxicity of the 
compound, since it is critically important for antibacterial agents not to be toxic for the 
host. An agent may have strong antibacterial activity but it would be unacceptable if 
induce aberrant functions or growth in organ specific tissues.  
Cytotoxicity of 7-O-m against mouse fibroblasts and human epithelial cells (L929 and 
HeLa respectively) was assessed. Microscopical analysis of the macrolactin 
antiproliferative effect suggested a toxic response because the cellular morphology of the 
treated cells was round. The control MeOH treated cells where not inhibited. In addition to 
microscopical analysis, the extent of the cytotoxic effect was quantified using the 
CyQUANT cell proliferation assay (Molecular Probes), a highly sensitive, fluorescence-
based microplate assay for determining numbers of cultured cells [53]. Against L929 cells, 
the effect of 7-O-m was evaluated in comparison to the other known macrolactins isolated 
in this study. A small reduction of cell proliferation was observed when the mouse 
fibroblasts were incubated with 15,6 µg/ml of 7-O-m rising to maximal inhibition (80 %) 
at 30 µg/ml. Macrolactin A showed higher cytotoxicity compare to the other two 
compounds (Figure 24A). The human cells were clearly less sensitive to 7-O-m than the 
mouse cells. The 7-O-m was able to inhibit the proliferation of HeLa cells at a 
concentration of 31.25 µg/ml. Cells cultures treated with 62.5 µg/ml of 7-O-m showed 
almost complete inhibition of growth (Figure 24B). 
Comparing the action of the new 7-O-m on human epithelial cells and mouse fibroblasts, it 
was observed that although the compound exert cytotoxicity at 31 µg/ml on both cell lines, 
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 human cell were found to be less sensitive to the drug toxic effect. The 7-O-m and 7-O-s 
possess lower cytotoxicity, compared with the macrolactin A, a compound known for its 
antitumoral activities. 
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Figure 24.  Inhibition of L929 cell proliferation by the three macrolactins (A), and 
comparison of inhibition of eukaryotic cells by 7-O-malonyl macrolactin A (B).  
M acrolactin  concentration (µg/m l)
0 20 40 60 80 100 120
%
In
hi
bi
tio
n
0
20
40
60
80
100
A
L-929 ce lls7-
O
-m
al
on
yl
7-
O
-s
uc
ci
ny
l
m
ac
ro
la
ct
in
 A
 
 7 -O -m a lo n yl m acro la c tin  c o n c en tra tio n  (µ g /m l)
0 20 40 60 80 100 120
%
In
hi
bi
tio
n
0
20
40
60
80
100
B
L -929
H eLa
 
 
 119
 4.16. Protein expression of methicillin resistant Staphylococcus aureus (MRSA 3) in 
the presence of 7-O-malonyl macrolactin A 
 
Proteomic experiments were carried out to investigate the influence of the 7-O-m in 
protein expression of the affected pathogens. MRSA 3 proteome changes were analysed 
following treatment of bacterial cultures with 7-O-m in comparison with untreated cells 
(Figure 25). The treatment was performed in MH media with 4µg/ml of 7-O-m for 16 
hours. This concentration caused a reduction in the growth rate but did not inhibited 
growth completely. Among 23 identified proteins which showed differences in their 
expression (Table 16), 15 were expressed only in treated cells (A9–A19 and A21-A24), 7 
were found only in untreated cells (C1-C4 and C6-C8) and one protein (C5, A20) was 
expressed in both, treated and untreated cells, in different amount. The latter protein, 
afterwards identified as ATP synthetase beta chain, was expressed in less amount in cells 
treated with 7-O-m. 
Sub-MIC of 7-O-m were able to induce important changes in the pattern of expression of 
several proteins. Of particular interest was the induction of the expression of a cell division 
protein, since TEM experiments, revealed that 7-O-m induced major changes over the cell 
division process of pathogenic bacteria. 
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Figure 25.  Two-dimensional gel electrophoresis of protein extracts of methicillin resistant Staphylococcus aureus (MRSA 3) treated with and 
without 7-O-malonyl macrolactin A. 
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Table 16.  Identified Proteins of Staphylococcus aureus MRSA 3 treated (A) and not (C) 
with 7-O-malonyl macrolactin A  
 
Spot 
No. Proteins 
Calculated 
pI 
Theoretical 
MW (kDa) 
Sequence 
Coverage 
% 
C1 ATP synthase alpha chain 4,91 55,7 26 
C2     
C3 transcription pleiotropic repressor 5,87 29,6 44 
C4 malate/quinone oxidoreductase 6,12 57,9 27 
C5 ATP synthase beta chain 4,68 52,2 51 
C6     
C7 Lipase 8,67 45 29 
C8     
A9     
A10 alkaline shock protein 23 5,13 19,9 23 
A11 
 
glucose-specific enzyme II, PTS 
system A component 
resolvase 
4,54 
 
9,62 
18,4 
 
24,61 
42 
 
29 
A12     
A13 conserved hypothetical protein 4,76 16,8 67 
A14 50S ribosomal protein L7/L12 4,63 13,3 60 
A15     
A16     
A17     
A18     
A19     
A20 ATP synthase beta chain 4,68 52,2 55 
A21 translational elongation factor TU 4,74 43,9 64 
A22 cell division protein 4,87 41,8 36 
A23 peptide methionine sulfoxide reductase 6,37 21,4 57 
A24 glyceraldehyde-3-phosphate 
dehydrogenase 
4,89 37,6 37 
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5. DISCUSSION 
 
Secondary metabolites are produced by microorganisms and serve survival functions for 
the organisms producing them. They act as competitive weapons used against other 
members of the community: as metal transporting agents; as agents of symbiosis between 
microbes and plants, nematodes, insects, and higher animals; as sexual hormones; and as 
regulators of cellular differentiation processes [5, 21, 65, 66]. Furthermore, their 
production appears to be a response to various ecological pressures within the 
environment. Microorganisms have shown tremendous potential as producers of novel 
natural products with important bioactivities, particularly with biomedical roles. Indeed, 
numerous and useful microbial products have been isolated, including growth inhibitors 
and promotants, antiviral, antitumor, fungicidal and bactericidal compounds [22, 67]. 
Despite their broad range of activities, the most studied secondary metabolites through the 
history have been the antibiotics. Currently, the appearance of multiple antibiotic 
resistance in pathogenic bacteria is increasing, compromising the clinical treatment of a 
growing number of infectious diseases. There is thus an urgent need for new drugs 
effective against current antibiotic resistant pathogens and opportunistic pathogens. 
However, during the last 20 years no new compounds have been introduced into the 
clinical practice [18, 68, 69].  
The search for active secondary metabolites produced by environmental isolates, using 
poorly explored microorganisms, could provide a new source for discovering novel 
bioactive compounds.  
This study was mainly aimed at the characterisation of novel secondary metabolites with 
antibiotic activity against microbial pathogens resistant to antibiotics currently used in the 
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 clinical practice. The vast majority of microorganisms in environmental samples remain 
unexplored and unknown, since access to this enormous reservoir of secondary metabolites 
producers has been hindered by the difficulty of culturing most of them. During the first 
phase of the study, efforts have been devoted to the recovery of secondary metabolites 
produced from microorganisms isolated from extreme environments. The identification of 
appropriate culture conditions for optimal production of bioactive metabolites was critical 
for facilitating the chemical identification, isolation and characterization of the bioactive 
molecules. Once isolation of the bioactive substance was achieved, structural analysis 
followed, which revealed whether or not the compounds were new. Subsequent to 
chemical characterization, determination of bioactivity spectrum of the purified 
compounds against a selected group of microbial pathogens provided information on the 
novelty of the activity. 
Extracts of cultures of a selected group of 2048 environmental microorganisms, isolated in 
different geographical habitats, were first screened to detect bioactive substances. 
Screening tests were performed to detect antibacterial, antiyeast, antifungal activities, as 
well as effect on eukaryotic cell proliferation and cytotoxicity. Of these extracts, 137 (7 %) 
obtained from different species belonging to 25 genera, showed interesting and 
biologically active metabolites, confirming microbial strains as a prolific source for active 
compounds. Moreover, the great taxonomical variety of the producer microorganisms 
demonstrates that the production of active secondary metabolites is not restricted to 
particular genera or species [1, 5, 22, 70]. While strains belonging to unusual genera may 
provide a higher probability of finding novel bioactive molecules, the fact that they are 
unusual implies little knowledge about their physiology and appropriate cultivation. 
Different species of Arthrobacter, Acinetobacter and Rhodococcus; together with 
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 Micromonospora floridensis, Curtobacter herbarum, Ochrobactrum tritici, in which only 
one isolate belonging to these species was selected as a producer, had lost the capacity to 
produce the bioactive compounds when cultivated in a second step. Several strategies of 
cultivation did not succeed in restoring the production capacity. Isolates of the Bacillus 
genus seem to continue to be promising sources of biologically active secondary 
metabolites [5], since, the analysis of the bioactive compounds produced by different 
species allowed to identify a new antibacterial compound. In addition, the experience 
accumulated with the Bacillus strains highlight once more the fact that the production of 
bioactive secondary metabolites is strain and not species related. 
Out of the 137 environmental strains that were selected as producers of active secondary 
metabolites, 59 % exhibited significant activity against multiresistant and reference strains 
of gram positive and gram negative bacteria and 58 % were active against fungi and yeasts.  
Of tested extracts, 8 % showed cytotoxicity against eukaryotic cells in terms of effects on 
cell morphology and proliferation. The effects induced in eukaryotic cells by the extracts 
reflects the extent of cytotoxicity of compounds that showed antimicrobial activity, in 
addition, they indicate potential antitumor activities.  
Eighty extracts were selected to assess possible insecticidal activities. Bacteria with toxic 
activity against insects have been widely investigated as a strategy for biological control of 
insect pests. Bacillus thuringiensis and Bacillus sphaericus are most useful bacteria in this 
regard and have been exploted in insect control for many years. However, the appearance 
of resistance to its toxins in different mosquitoes species has renewed the interest in the 
search for alternatives, one of which is new active bacterial products with insecticidal 
activity [71, 72]. 35 % of the evaluated extracts showed strong larvicidal activity against 
Anopheles albimanus (mosquito vector of human diseases) and Musca domestica. 
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 Although the number of target strains was low and the concentration of the active 
compound(s) in the tested extracts was unknown, these results suggest that further 
investigations are warranted. 
As mentioned above, a critical element for the establishment of an efficient production of 
secondary metabolites is the condition in which the producer microorganism is grown [73]. 
It have been reported that over 40 % of microorganisms produce active secondary 
metabolites when they are freshly isolated from nature but this ability is lost in many of 
them during the storage [5]. Therefore an aim of this study was the establishment of 
adequate culture conditions to obtain sustained production of the bioactive compounds. 23 
% of the strains producing secondary metabolites with antibacterial activity lost this 
capacity prior to the preparation of a second extract. Several culture conditions and media 
with different compositions were tested, not generally effective medium for recovery of 
production of activity was found, even with strains of given species, indicating that the 
stability of secondary metabolite production is not species related, but, depends on the 
intrinsic properties of the strain. For example, with a Bacillus laterosporus strain after 
testing several media described in the literature as optimal for the secondary metabolite 
production in Bacillus [23, 63, 74], the capacity to produce compounds with antibacterial 
activity was recovered in Cooper medium [63]. Different cultivation parameters were used 
in order to increase the yields of activity in this medium, including changes in all 
components of the medium, specially Na2HPO4, a known critical component for optimal 
production. Furthermore, several compounds for promoting secondary metabolite 
production are described in literature like Mg+2, Zn+, Mn+2, Fe+, or substances like DMSO 
[23, 64, 75, 76]. In this work, the addition of manganese 0.004 % gave the best yield of 
active compounds produced in Cooper medium by the B. laterosporus strain.  
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 Once stable production of secondary metabolites with antimicrobial activity was 
stablished, and/or the production was enhanced, different approaches to identify and 
characterise the substances responsible for the activity were investigated. The first 
methodology implemented was TLC, combined with bioactivity tests, but the little amount 
of active substances isolated was not sufficient to proceed with the characterisation. On the 
other hand, TLC was extremely useful to compare the patterns of activities of the different 
producers strains belonging to the same genera. When selected producers belonged to the 
same species and showed the same TLC pattern of active compounds, only the extract with 
the highest activity was further characterised. The second approach was to purify the active 
compounds using silica gel column chromatography. While this method can be rapid and 
effective to obtain large quantities of an active compound, it mostly resulted in a sample 
containing the active substance that needs further purification. HPLC was the third and 
most successful strategy investigated and became the routine approach for identification of 
the active compounds contained in bioactive extracts. The correlation between peaks in the 
chromatogram and biological activity levels in the different HPLC fractions, allowed the 
identification of the active compounds contained in the extracts. HPLC-UV-MS analysis 
provided the absorption spectra and masses of the active compounds. Comparison of these 
data with those of known structures in databases allowed identify compounds as known or 
unknown, and provided the structures of those that were known. 
Over 50 compounds produced by 17 microorganisms with high antibacterial and/or 
antifungal activity were recognized, mostly known structures. The substances more 
commonly found were the amicoumacins, antibiotics previously reported with activities 
against Staphylocccus aureus [77]. Other commonly found structures included bacillaene, 
difficidin and oxydifficidin reported as inhibitors of protein synthesis with activity against 
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 a wide spectrum of bacteria including Proteus vulgaris, Pseudomonas aeruginosa, 
Escherichia coli, Serratia marcescens and Bacillus thuringiensis [27, 78]. All the above 
mentioned antibiotics were presents in the extracts produced by different strains of the 
Bacillus genus. Additionally, bogorols [39], bacillomycins [79-81], actinomycins [82] and 
moenomycins [83, 84], all known antibacterial compounds produced by Bacillus and 
Streptomyces strains were found. Compounds with activity against fungi and yeasts were 
identified as lagosin and isolagosin and filipins that are produced by Streptomyces strains 
[85, 86]. However, even known compounds can be discovered to posses unknown 
activities. Recognised known compounds that demonstrate excellent novel in vitro activity 
with respect to the originally described molecule, particularly against newly isolated 
resistant pathogens, require additional studies to revaluate their chemical structure and to 
assess their novelty. The complete characterisation of some active compounds with 
structures that included polyketides, terpenes and peptides, was not possible because of the 
low amount produced which was not sufficient for structure elucidation. Particularly with 
peptides the limitations were the complexity of the characterisation, in some cases their 
chemical properties exceeded the limit of the available equipment (e.g. molecular masses 
above 1800) and lack of UV spectra. 
A new macrolactin compound with bacteriostatic effect against staphylococci and 
enterococci, particularly against methicillin resistant Staphylococcus aureus and 
vancomycin resistant enterococci clinical isolates, was discovered and characterised. The 
producer microorganism was isolated in Indonesia and identified according to pheno and 
genotypic characteristics as Bacillus subtilis. The strain produced three macrolactins and 
around seven different compounds with antimicrobial activity belonging to the chemical 
groups of bacillomycins, difficidins and aromatic lipopeptides. Among these, of particular 
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 interest was the new compound 7-O-malonyl macrolactin A (7-O-m).  
The macrolactins are macrolides containing three separate diene structure elements in a 24-
membered lactone ring [62, 87, 88]. These compounds have been reported previously as 
being products of Bacillus sp., unclassifiable marine bacteria and Actinomadura sp. [44, 
62, 87, 88]. Six macrolactins were first described in 1989, having interesting 
pharmacological properties with macrolactin A as the most active [87]. In 2000, three new 
macrolactins with weak antibacterial activities were isolated [62] and in 2001, the isolation 
of 7 new macrolactins was reported [88]. Until now, sixteen macrolactins have been 
chemically described and macrolactins A and E have been chemically synthesised [40, 41, 
69, 89, 90]. The Bacillus subtilis strain analysed during this study produced the known 
compounds macrolactin A and 7-O-succinyl macrolactin A (7-O-s), and the new 
compound 7-O-m. The structural differences between these three macrolactins are located 
at residue C-7 and involves a hydroxyl group in macrolactin A, a succinic acid residue in 
7-O-succinyl and a malonyl group in the new compound 7-O-m.  
Macrolactin A has been shown to inhibit murine melanoma cancer cells in in vitro assays, 
to inhibit replication of Herpes simplex viruses, to protect T-lymphoblast cells against 
human HIV viral replication [44, 62, 87, 88], and to inhibit squalene synthase [91]. 
The macrolactins have been shown to posses antibacterial activity against Staphylococcus 
aureus and Bacillus subtilis [44, 62, 87, 88] and, to our knowledge, no antibacterial 
activity against multi-resistant clinical isolates has been reported. Nagao et al. [88], 
reported MICs of macrolactins A and F to M between 5 and >100 mg/l, Staphylococcus 
aureus being the most sensitive microorganism tested. Macrolactin A was the most potent 
antibiotic of the group characterised and showed activity against Staphylococcus aureus 
with MIC of 10 mg/l and 28 mm of inhibition using 100 µg discs [88]. The antimicrobial 
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 activity attributed to macrolactin A varies in the different publications. Gustafson et al. 
[87] reported that macrolactin A inhibited the growth of Staphylococcus aureus and 
Bacillus subtilis at concentrations between 5 and 20 µg/disc. Jaruchoktaweechai et al. [62] 
reported that macrolactin A and 7-O-Succinyl macrolactin A (7-O-s), exhibited 
antibacterial activity against the same bacteria with inhibition zones of 8-28 mm at 5-100 
µg/disc respectively, but none of the compounds were tested against clinical isolates, 
particularly multi-resistant strains.  
The activities obtained in this study with macrolactin A and 7-O-succinyl macrolactin A 
(7-O-s) produced by Bacillus subtilis strain were bacteriostatic in vitro against 
Staphylococcus aureus, with inhibitions zones of approximately 25 mm with 50 µg discs. 
The 7-O-m showed higher antibacterial activities particularly against methicillin resistant 
Staphylococcus aureus and vancomycin resistant enterococci strains with inhibition zones 
of between 15 and 41 mm.  
Liquid tests showed that in addition to the MIC, another concentration value (sub-MIC) 
could clearly be identified, at which a strong inhibition of the bacterial growth was 
observed. The 7-O-m inhibited strongly the growth of Staphylococcus aureus, methicillin 
resistant Staphylococcus aureus, Enterococcus faecalis, vancomycin resistant enterococci , 
Burkholderia cepacia small colony variants and Candida krusei, at concentrations between 
0.06 and 32 µg/ml, even though the MICs for all the strains were ≥ 128 µg/ml. 
In order to clarify this inhibitory effect, kinetics of growth at these sub-MICs were 
performed. Interestingly, the 7-O-m showed a more pronounced bacteriostatic effect on the 
growth of resistant bacteria methicillin resistant Staphylococcus aureus and vancomycin 
resistant enterococci, where the viable counts do not increase significantly over the 
inoculum values during 24 hours. To our knowledge, there are no studies reporting the 
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 kinetics of growth of strains treated with any of the macrolactins previous characterised. 
B. cepacia SCV was the only gram negative strain affected by the 7-O-m, however, the 
fact that the 7-O-m was able to inhibit the growth of the small colony variants and not the 
wild type B. cepacia, suggests a specific activity against slow growing bacteria, an 
interesting property that needs further investigation.  
The post antibiotic effect (PAE) of 7-O-malonyl macrolactin was performed at the sub-
MICs values tested in the kinetics studies, in order to further investigate the bacteriostatic 
activity of the substance at these concentrations. PAE is a term used to describe 
suppression of bacterial growth that persist after brief exposure of organisms to 
antimicrobials. A prolonged PAE play a beneficial role because during the time that the 
bacterial pathogen remain suppressed as a result of PAE, they may be sensitive to the lethal 
effects of patient leukocytes. PAE values, at sub-MICs, were significantly longer with E. 
faecium vancomycin resistant - ampicillin resistant (VRAR) than with methicillin resistant 
Staphylococcus aureus (MRSA 3). During the pre-PAE time, in which the cells were 
incubated in presence of the antibiotic, the bacteriostatic effect was confirmed, because no 
growth was detected at this stage. After removing the antibiotic, the treated E. faecium 
vancomycin resistant - ampicillin resistant (VRAR) was not able to recover the normal 
growth during a long time (PAE 2.31 h) indicating that the compound, at sub-MICs, 
induced an extended damage in these bacteria. There are some previous reports in the 
literature concerning the PAE sub-MIC effects, which seems to be more clinical relevant 
compared with the PAE, since exposure to supra-inhibitory concentrations will be always 
followed by sub-MICs in vivo [92]. A long PAE at sub-MICs, considered over 0.30 h, will 
contribute to the antibacterial effects of an antibiotic. In addition, it is well known, that 
sub-MICs inhibit bacterial virulence and influence the response of the immune system in 
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 vivo [92]. 
Transmission electron microscopy observations of the methicillin resistant Staphylococcus 
aureus and vancomycin resistant Enterococcus faecium strains treated with 7-O-m, 
revealed alterations in the cell division process, suggesting that separation of the daughter 
cells was inhibited. Approximately 60 % of the methicillin resistant Staphylococcus aureus 
(MRSA 3) the treated bacteria were observed in packets of not separated cells, lacking 
complete formation of cells walls, in which multiple asymmetrical initiation points of 
division were observed. Treatment of E. faecium vancomycin resistant - ampicillin 
resistant (VRAR) with 7-O-m at sub-MICs, induced the formation of chains of not 
separated bacterial cells in which several septation initiations were observed. Morphology 
alterations are known to be induced by compounds that inhibit the cell wall synthesis, such as 
penicillins, and by compound P, the active principle of crude tea extract. Methicillin resistant 
Staphylococcus aureus and Staphylococcus aureus cells grown in presence of these 
compounds, produced a thickened cell wall [93, 94]. Furthermore, abnormal morphology and 
the appearance of amorphous material on the surface of glycopeptide-treated bacteria were also 
described for Staphylococcus aureus and enterococci [95-97]. Unusually, the formation of 
buds was observed at the points of cell division in Burkholderia. cepacia SCV and cells with 
abnormal shape and size, smaller and rounded than usual, were also observed. The mechanism 
by which the 7-O-m exerts its morphological effects, through interfering with cell separation, 
is interesting because pseudomulticellular clusters are unable to disseminate daughter cells for 
spreading an infection, and should therefore be less virulent. The characterization of the 7-O-m 
mode(s) of action, could provide interesting new insights in the search for novel drug targets 
for future drug discovery. 
In addition to the antibacterial activities, macrolactin A has previously been reported to 
show cytotoxic and antiviral effects [44, 62, 87, 88]. The macrolactin A isolated in this 
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 study showed higher cytotoxicity than the other two macrolactins substituted at C-7 which 
suggests that the eukaryotic cell toxic effect could be reduced by varying the C-7 
substituent. 
The 7-O-m studied here, possessed higher antimicrobial activity and lower cytotoxicity 
than the two known macrolactins produced by the same strain, and other macrolactin 
variants described in the literature.  
The antibacterial activity of 7-O-m was clearly bacteriostatic. Bacteriostatic agents (e.g., β-
lactams, chloramphenicol, clindamycin, macrolides and linezolid) have been effectively 
used for treatment of a range of bacterial infections, including endocarditis, meningitis, and 
osteomyelitis, indications that are considered to require bactericidal activity [98]. 
Furthermore, a bacteriostatic agent like clindamycin has been shown to completely inhibit 
the toxic shock syndrome toxin-1 production by Staphylococcus aureus [99] and toxin 
production in both streptococci and staphylococci [100] suggesting the potential efficacy 
of bacteriostatic agents in the treatment of infections. It will be interesting to investigate 
the influence of 7-O-m in the production of virulence factors by methicillin resistant 
Staphylococcus aureus and vancomycin resistant enterococci. Since has been clearly 
demonstrated the efficacy of combination antibiotic therapy, it will be interesting to 
evaluate synergistic interactions of the 7-O-m with other antibiotics.  
Proteomic experiments were carried out to investigate the influence of the 7-O-m on 
protein expression by methicillin resistant Staphylococcus aureus. Different patterns of 
protein expression were obtained in presence and absence of the 7-O-m. Among 23 
identified proteins which showed differences in their expression, 15 were expressed only in 
treated cells, 7 were found only in untreated cells and one protein was expressed in both, 
treated and untreated cells, in different amount. Of particular interest was the induction of 
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 expression of a cell division protein, since ultrastructural analysis, revealed that 7-O-m 
induced major changes in the cell division process of pathogenic bacteria. Further 
proteomic studies should reveal important insights into the mechanism of action of 7-O-m . 
During the last years, significant advances have occurred in the field of proteomics that are 
applicable to antimicrobial lead discovery [101-103]. Furthermore, this method is a 
recognized tool for the investigation of the action mechanism of antibiotics according to 
the express for Bandow et al [101] and Bruneau et al [102].  
 
To conclude, it was described here the discovery and characterisation of a new variant of 
macrolactin that exhibits important hitherto undescribed clinically relevant activities, 
namely inhibition of multiresistant gram positive pathogens and of small colony variant of 
Burkholderia cepacia. This compound exerts an interesting effect on cell morphology and 
appears to inhibit completion of septation during cell division. It shows promise for further 
development as a new antibiotic and should be further characterised in terms of its mode of 
action and pharmacological activities. 
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6. SUMMARY 
2048 microorganisms isolated from different environments were evaluated for their 
production of secondary metabolites with biological activities. 
In order to enable preliminary screenings, the strains were cultivated on different culture 
media according to their origin of isolation. Extracts obtained from 137 strains showed 
biological activity, of them, 81 were active against microbial targets, 28 exhibited 
significant activity against insects and 120 were cytotoxic, affecting the morphology or 
inhibited the proliferation of eukaryotic cells. 
The bioactive extracts were chemically analysed and over 50 compounds were recognized 
as previously reported structures. Three macrolactin compounds were identified, among 
them, a new structure. These compounds were selected for purification, structure 
elucidation and investigation of their biological properties. 
The new compound, designated 7-O-malonyl macrolactin A (7-O-m) and produced by a 
Bacillus subtilis strain isolated from Indonesia, belongs to the macrolactin family, a group 
of compounds known for their antiviral and cytotoxic properties. When the in vitro 
antibacterial activities of the three purified macrolactins were tested, the 7-O-m was the 
most active, particularly against gram positive bacteria. Of great interest, is the capacity of 
7-O-m to inhibit the bacterial growth of methicillin resistant Staphylococcus aureus, 
vancomycin resistant enterococci and small colony variants of Burkholderia cepacia. 
Through different biological tests, MIC, sub-MIC, PAE and growth curves in presence of 
7-O-m, the nature of the activity was identified as bacteriostatic. The inhibition of the 
bacterial growth in the presence of 7-O-m was associated with an alteration of the 
replication process and changes in the pattern of protein expression as observed in TEM 
 135
 studies and proteomic preliminary studies. 7-O-m shows promise for further development 
as a new antibiotic and should be further characterised. 
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 7. FUTURE PROSPECTS 
 
Through the history, secondary metabolites have been and continue being an unlimited 
source of natural products with different activities, one of these, their use as antibiotics. 
Nowadays, when the antibiotics used in the medical practice have decreased effect over the 
new isolated multiresistant strains, it is of the special interest to discover new compounds 
active against resistant pathogens. In this study, 2048 microbial isolates from different 
environments were evaluated for their production of secondary metabolites with biological 
activities. In order to further exploit the potential of the extracts produced, other 
procedures should be developed for the incorporation of new targets into the screening. 
Furthermore, applications for known antimicrobial compounds could be discover.  
The biological activity of the new discovered 7-O-malonyl macrolactin A (7-O-m), could 
be further investigated as follows: 
- Evaluation of the activity against other important microbial pathogens as Mycobacterium 
tuberculosis and Streptococcus strains. 
- Combination of 7-O-m with known antibiotics to evaluated possible synergistic activities 
against multiresistant pathogens.  
- Investigation of the effect in slow growing microorganisms, particularly strains of 
Burkholderia cepacia isolated from cystic fibrosis patients. 
- Effect of the 7-O-m on the expression of virulence factors produced by gram positive as 
well as gram negative bacteria. 
- Elucidation of the mechanism of action of 7-O-m using proteomics. 
- Identification of the genes involved in the production of 7-O-m . 
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9. APPENDIX: MEDIA USED 
 
9.1. OM medium 
Starch 1.0 g 
Glucose 1.0 g 
Peptone 1.0 g 
Yeast extract 1.5 g 
Distilled water up to 980 ml and autoclave. To solid media add 20 g/l agar. After 
autoclaved add 10 ml of solutions A and B, and 1 ml of solution C and D. 
 
Solution A 
KH2PO4 5 g 
K2HPO4 5 g 
Distilled water up to 1000 ml and autoclave. 
 
Solution B 
MgSO4 17 g 
NaCl 1.0 g 
MnSO4 0.7 g 
CuSO4 0.06 g 
Distilled water up to 1000 ml and autoclave. 
 
Solution C 
FeSO4.7H2O 0.1 g 
Na3-Citrate.2H2O 2.2 g 
Ammonium acetate 2 g 
Na-thioglycalase 0.75 g 
Na2-succin.6H20 3.3 g 
Distilled water up to 100 ml and autoclave by filtering 
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 Solution D 
Biotin 10 mg 
Nicotinic acid amide 35 mg 
Thiamine HCl 30 mg 
p-Aminobenzoid acid 20 mg 
Pyridoxal hydrochloride 10 mg 
Ca-pantothenate 10 mg 
Vitamin B12 5.0 mg 
Distilled water up to 100 ml and autoclave by filtering 
 
 
9.2. Medium X Gen 
Glucose 10 g 
Peptone 10 g  
Yeast extract  15 g  
Solution A 10 ml (100 ml: KH2PO4 0.50 g, K2HPO4 0.50 g) 
Solution B 10 ml (100 ml: NaCl 0.10 g, MgSO4.7H2O 3 g, 
CuSO4.5H2O 0.01 g, MnSO4.5H2O 0.10 g)  
Solution C 1 ml (100 ml: FeSO4.7H2O 0.10 g, Na3 citrate 2 
g) 
solution D 10 ml(100 ml: CaCl2.2H2O 0.20 g ZnCl2 0.20 g). 
Distilled water up to 1000 ml and autoclave. 
 
9.3. Bpm (Bacillus pumilus medium) 
Glucose 20 g 
KH2PO4 2.0 g 
MgSO4.7H2O 0.5 g  
NaCl 3.0 g 
FeSO4 0.5 mg 
Soybean 20 g 
Complete the volume to 1L and autoclave. 
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 9.4. Seed Medium 
Yeast 12 g  
CaCO3 2.0 g  
Pharmamedia 10 g  
Glycerol 15 g 
Distilled water up to 1000 ml and autoclave. 
 
9.5. OMLP (Optimal medium for lipopeptide production) 
Sucrose 20 g 
KH2PO4 1.9 g 
MgSO4 0.45 g 
KI 0.002 mg  
FeCl3.6H2O 0.005 mg  
MnSO4.H2O 3.6 g 
Yeast 7 g 
ZnSO4.7H2O 0.14 mg, 
NaMoO4 0.004 mg,  
H3BO3 0.01 mg,  
Peptone 30 g 
Distilled water up to 1000 ml and autoclave. 
 
9.6. EM 
Yeast extract 5.0 g 
Tryptone 20 g 
NaCl 5.0 g 
Distilled water up to 1000 ml and autoclave. Add glucose 5 g/L. 
 
9.7. Cooper Medium 
Glucose 30 g 
KH2PO4 4.1 g 
MgSO4 0.1 g 
Na2HPO4 5.7 g 
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 CaCl2 0.8 mg 
NH4NO3 4.0 g 
Distilled water up to 1000 ml and autoclave. 
 
9.8. Medium 109 DSM - AOLPA (Artificial Organic Lake peptone agar)  
NaCl 100.0 g  
MgCl.6H2O 5.0 g  
MgSO4.7H2O 9.5 g  
KCl 5.0 g  
CaCl2.2H2O 0.2 g  
(NH4)2SO4 0.1 g  
K2SO4 0.1 g  
Peptone 5.0 g  
Yeast Extract 1.0 g  
Distilled water up to 960 ml. Adjust the pH to 7.0 + 0.2. Cool to 50°C. Aseptically add 
20.0 ml of solution 1 and 20.0 ml of solution 2 and 1.0 ml of solution 3. To solid media 
add 15 g/l agar. 
 
Solution 1: Hutner's modified salts solution (HMSS) 
C6H9NO6 10.0 g  
MgSO4.7H2O 29.7 g 
CaCl2.H2O 3.3 g  
Na2MoO4.2H2O 12.7 mg  
FeSO4.5H2O 99.0 mg  
Metals 44 (S1) 50.0 ml 
Distilled water up to 1000 ml 
Neutralise the C6H9NO6 with KOH. Dissolve the remaining ingredients and adjust the pH 
to 7.0 + 0.2 with KOH or H2SO4. Sterilise at 121°C for 15 minutes and store at 4°C. 
 
Solution 2 : Phosphate supplement (PS) 
K2HPO4 2.5 g  
KH2PO4 2.5 g 
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 Distilled water up to 1000 ml 
Dissolve and sterilise at 121°C for 15 minutes. Store at 4°C. 
 
Solution 3 : Artificial Organic Lake vitamin solution (AOLV) 
Cyanocobalamin 0.1 mg  
Biotin 2.0 mg 
Calcium Pantothenate 5.0 mg 
Folic Acid 2.0 mg  
Nicotinamide 5.0 mg  
Pyridoxine Hydrochloride 10 mg (Merck 1.07527) 
Riboflavin 5.0 mg  
Thiamine Hydrochloride 5.0 mg  
Distilled water up to 1000 ml. Dissolve and sterilise by filtration (0.22 µm). Store at 4°C. 
 
Metals 44: 
Na-EDTA  0.25 g 
ZnSO4 .7 H2O 1.1 g 
FeSO4 .7 H2O 0.5 g 
MnSO4 .H2O 0.15 g 
CuSO4 .5 H2O 0.04 g 
Co(NO3)2 . H2O 0.024 g 
Na2B4O7 .10 H2O 0.017 g 
Distilled water 100 ml 
Dissolve the EDTA and add a few drops of concentrated H2SO4 to retard precipitation of 
the heavy metal ions. 
 
9.9. Enrichment Medium 
Na2CO3 3.0 g 
KCl 2.0 g 
MgSO4.7H2O 1.0 g 
NaCl 100 g 
Yeast Extract 10 g 
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 MnCl2.4H2O 0.36 mg 
FeSO4 50 mg 
Distilled water up to 1000 ml and autoclave. 
 
9.10. Mueller Hinton Agar (MH) 
MH agar 38.0 g 
Distilled water up to 1000 ml and autoclave. 
 
9.11. Mueller Hinton Broth (MH) 
MH Broth 21.0 g 
Distilled water up to 1000 ml and autoclave. 
 
9.12. Medium 61 DSM (M61) 
Tryptone 10 g 
Sucrose 10 g 
Yeast extract 2 g 
FeSO4.7H2O 0.2 g 
Na2SO3 0.2 g 
Na2S2O3.5H2O 0.08 g 
Distilled water up to 1000 ml and autoclave. pH: 6.8 –7.8 
Add after autoclaved 1 ml/10 ml medium of each one of this substances: 
NaHCO3 4.2 g/100 ml 
Na2CO3 5.3 g/100 ml 
 
9.13. Medium 284 DSM (Halomonas pantelleriensis) 
Yeast extract 10 g 
Na citrate 3.0 g 
KCl 100 g 
NaCl 100 g 
Na2CO3 100 g 
MgSO4.7H2O 1.0 g 
Distilled water up to 1000 ml and autoclave. 
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9.14. GEN medium 
Glucose 2.0 g 
Yeast extract 3.0 g 
NaCl 1.0 g 
Distilled water up to 1000 ml and autoclave. 
 
9.15. SMM (Synthetic Malate medium)  
DL-Malic acid 5.0 g 
KOH 4.5 g 
KH2PO4 0.6 g 
K2HPO4 0.4 g 
MgSO4.7H2O 0.2 g 
NaCl 2.5 g 
CaCl2 0.02 g 
MnSO4.H2O 2.0 mg 
FeEDTA (0.66 w/v) 10 ml 
Biotin 0.1 mg 
NH4Cl 0.5 g 
Yeast extract 0.1 g 
Distilled water up to 1000 ml. Adjust pH to 7.2. 
 
9.16. ANA (Alkaline Nutrient Agar) 
Peptone 5.0 g 
Meat extract 3.0 g 
Distilled water up to 1000 ml. After sterilization add sterile 1 M Na-sesquicarbonate 
solution (1 ml in 10 ml) to achieve a pH of 9.7. 
 
Na-sesquicarbonate solution: 
NaHCO3 4.2 g 
 Na2CO3 anhydrous 5.3 g 
Distilled water up to 1000 ml. 
 155
  
9.17. Landy Medium 
Glucose 20 g 
KH2PO4 1.0 g 
MgSO4.7H20 0.5 g 
FeSO4.6H2O 1.2x10-3 g 
CuSO4.5H2O 1.6x10-3 g 
MnSO4 0.4x10-3 g 
L-Glutamic acid 5.0 g 
Yeast extract 10 g 
Distilled water up to 1000 ml. Adjust pH: 7.5 
 
9.18. Difco Nutrient broth (DSM) 
MgSO4 10 ml of a solution 1.2 % 
KCl 10 ml of a solution 10 %  
FeSO4 0.15 g 
MnCl2 1.3 g 
NaOH 40 g 
Ca(NO3)2 16.4 g 
 
9.19. NBG 
Nutrient Broth 8.0 g 
Glucose 5.0 g 
Distilled water up to 1000 ml and autoclave. 
 
9.20. Medium 90 DSM - Malt Extract Peptone Agar 
Malt extract 30 g 
Soya peptone 3.0 g 
Distilled water up to 1000 ml. Adjust pH to 5.6. Sterilize at 121°C for 10 min. To solid 
media add 15 g/l agar. 
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 9.21. Medium 220 DSM - CASO AGAR  
Peptone from casein 15 g  
Peptone from soy meal 5.0 g 
NaCl 5.0 g 
Adjust pH to 7.3. Distilled water up to 1000 ml and autoclave. To solid media add 15 g/l 
agar. 
 
9.22. Medium 545 DSM - TSB (Tryptone soy broth) 
Peptone from casein 17.0 g 
Peptone from soy meal 3.0 g 
D(+)-Glucose 2.5 g 
NaCl 5.0 g 
K2HPO4 2.5 g 
Adjust pH to 7.3.Distilled water up to 1000 ml and autoclave. 
 
9.23. MSAM (Minimal Salt Agar Medium) 
MgSO4.7H2O 0.5 g 
K2HPO4 0.7 g 
KH2PO4 0.3 g 
FeSO4.H2O 0.01 g 
ZnSO4 0.001 g 
MnCl2 0.001 g 
Distilled water up to 1000 ml and autoclave. 
 
9.24. BHI (Brain heart infusion)  
Brain Heart Infusion 18.5 g 
Distilled water up to 1000 ml and autoclave. 
 
9.25. St-1 (Streptomyces medium 1) 
Maltose 10 g 
Glycine 4.5 g 
K2HPO4 0.12 g 
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 KH2PO4 0.12 g 
NaCl 1.0 g 
CaCl2 0.1 g 
Traces 20 ml 
Distilled water up to 1000 ml and autoclave. 
Traces: 
FeSO4.7H2O 1.0 g 
MnCl2.4H2O 1.0 g 
ZnSO4.H2O 1.0 g 
CaCl2 1.0 g 
Distilled water up to 100 ml. 
 
9.26. St-2 (Streptomyces medium 2) 
MgSO4.7H2O 0.6 g 
K2HPO4 3.5 g 
L-Asparagine 2.0 g 
Glycerol 10 ml 
MOPS buffer 21 ml 
Traces 1 ml 
Distilled water up to 1000 ml and autoclave. Adjust pH 6.8. 
 
9.27. St-3 (Streptomyces medium 3) 
Glucose 75 g 
NH4Cl 9.0 g 
K2HPO4 1.0 g 
MSG 5.0 g 
CaCO3 5.0 g 
MOPS 21 
Salt 1 20 ml 
Distilled water up to 1000 ml and autoclave. 
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 Salt 1: 
MgSO4.7H2O 28,9 g 
FeSO4.7H2O 0.5 g 
ZnSO4.7H2O 0.5 g 
MnSO4.H2O 0.1 g 
CuSO4.5H2O 0.05 g 
CaCl2.6H2O 0.04 g 
Distilled water up to 1000 ml. 
 
9.28. St-4 (Streptomyces medium 4) 
Tryptone 17 g 
Soy peptone 3.0 g 
NaCl 5.0 g 
K2HPO4 1.25 g 
Distilled water up to 1000 ml and autoclave. 
 
9.29. St-6 (Streptomyces medium 6) 
Soy bean meal 20 g 
Casamino acids 10 g 
Yeast extract 1.0 g 
Meat extract 1.0 g 
Lysine HCl 1.0 g 
Na2S2O3.5H2O 0.5 g 
MgSO4.7H2O 0.5 g 
K2HPO4 0.5 g 
Distilled water up to 1000 ml and autoclave. 
 
9.30. Mic-1 (Micromonospora natural medium 1) 
Beef extract 3.0 g 
Tryptone 5.0 g 
Glucose 8.0 g 
Starch 24 g 
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 Yeast extract 8.0 g 
CaCO3 1.0 g 
NaNO3 2.0 g 
Ca(NO3)2 1.0 g 
Co(NO3)2.6H2O 5x10-3 g 
(NH4)6(Mo7O24).4H2O 2x10-4 g 
FeSO4.7H2O 5x10-3 g 
CuCl2.2H2O 2x10-4 g 
ZnCl2 2x10-4 g 
MnSO4.4H2O 3x10-3 g 
Distilled water up to 1000 ml and autoclave. 
 
9.31. Mic-10 (Micromonospora medium 10) 
Glucose 10 g 
Starch 24 g 
Peptone 3.0 g 
Meat extract 3.0 g 
Yeast extract 5.0 g 
CaCO3 4.0 g 
Distilled water up to 1000 ml and autoclave. 
 
9.32. Mic-15 (Micromonospora medium 15) 
Soluble starch 20 g 
Glucose 5.0 g 
NH4Cl 5.0 g 
K2HPO4 0.5 g 
MgSO4.7H2O 0.5 g 
CaCO3 1.0 g 
NH4NO3 4.0 g 
(NH4)2SO4 6.5 g 
Distilled water up to 1000 ml and autoclave. 
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 9.33. PM-5 
Dextrin 12 g 
Cottonseed flour 30 g 
Wheat germ 12 g 
Dry yeast 1.2 g 
CaCO3 6.0 g 
MgSO4 6.0 g 
K2HPO4 2.4 g 
FeSO4.7H2O 0.8 g 
CoCl2.6H2O 0.02 g 
Distilled water up to 1000 ml and adjust pH 7.2 with 1N NaOH. 
 
9.34. Medium 125: Methylobacterium medium 
KNO3 1.0 g 
MgSO4.7 H2O 0.2 g 
CaCl2 . 2 H2O 0.02 g 
Na2HPO4 0.23 g 
NaH2PO4 0.07 g 
FeSO4 .7 H2O 1.0 mg 
CuSO4 .5 H2O 5.0µg 
H3BO3 10µg 
MnSO4 .5 H2O 10µg 
ZnSO4 .7H2O 70µg 
MoO3 10µg 
Distilled water up to 1000 ml. Add 5 ml MeOH or incubate under methane-air (4:1). 
Adjust pH to 6.8. To solid media add 12 g/l agar. 
 
 
9.35. Medium 457 DSM - Mineral medium (Brunner) 
Na2HPO4 2.4 g 
 KH2PO4 1.5 g 
 (NH4)2SO4 0.5 g 
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  MgSO4 . 7 H2O 0.2 g 
 CaCl2 . 2 H2O 0.05 g 
 Trace element sol. SL-4 10 ml 
Distilled water up to 1000 ml. Adjust pH to 6.9. 
 
Trace element solution SL-4: 
EDTA 0.50 g 
FeSO4 . 7 H2O 0.20 g 
Trace element solution SL-6 100 ml 
Distilled water up to 1000 ml 
 
9.36. Trace element solution SL-6: 
ZnSO4 . 7 H2O 0.10 g 
MnCl2 . 4 H2O 0.03 g 
H3BO3 0.30 g 
CoCl2 . 6 H2O 0.20 g 
CuCl2 . 2 H2O 0.01 g 
NiCl2 . 6 H2O 0.02 g 
Na2MoO4 . 2 H2O 0.03 g 
Distilled water up to 1000 ml. 
 
9.37. Medium 606 DSM - Colby and Zathman medium 
K2HPO4 1.20 g 
KH2PO4 0.62 g 
CaCl2 . 6 H2O 0.05 g 
MgSO4 . 7 H2O 0.20 g 
NaCl 0.10 g 
FeCl3 . 6 H2O 1.0 mg 
(NH4)2SO4 0.5 g 
CuSO4 . 5 H2O 5.0µg 
MnSO4 . 5 H2O 10µg 
Na2MoO4 . 2 H2O 10µg 
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 H3BO3 10µg 
ZnSO4 . 7 H2O 70µg 
CoCl2 . 6 H2O 5.0µg 
Purified agar 15 g 
MeOH 2.0 ml 
Distilled water up to 1000 ml. Adjust pH to 7.0. Autoclave at 121°C for 15 min. Cool to 
50°C. Add a filter-sterilized solution of MeOH to give a final concentration of 0.2 %. 
 
9.38. Medium 805 DSM - Methylobacterium thiocyanatum medium 
KSCN 0.25 g 
MgSO4 . 7 H2O 0.10 g 
K2HPO4 1.50 g 
Na2HPO4 . 2 H2O 7.90 g 
Glucose  4.50 g 
FeSO4 . 7 H2O (2 %) 1.0 ml 
Distilled water up to 1000 ml. To solid media add 15 g/l agar. Sterilize medium at 115°C 
for 10 minutes. 
 
9.39. Alc-1 (Alcaligenes medium 1) 
Na2HPO4 9.0 g 
KH2PO4 1.5 g 
NH4Cl 1.0 g 
MgSO4.7H2O 0.2 g 
Fe NH4 Citrate 1.2 mg 
CaCl2 20 mg 
Hoagland Solution 2.0 ml 
NaHCO3 0.5 g 
Distilled water up to 1000 ml and autoclave. 
 
9.40. Alc-2 (Alcaligenes medium 2) 
Glucose Monohydrate 10 g 
Yeast extract 1.0 g 
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 Polypeptone 10 g 
Globe corn starch 20 g 
Distilled water up to 1000 ml and autoclave. 
 
9.41. KMA (King medium A) 
Peptone 20 g 
Glycerol 10 ml 
K2SO4 10 g 
MgCl2 10 g 
Distilled water up to 1000 ml and autoclave. 
 
9.42. KMB (King medium B) 
Protease peptone n.3 20 g 
Glycerol 10 ml 
K2HPO4 1.5 g 
MgSO4.7H2O 1.5 g 
Distilled water up to 1000 ml and autoclave. 
 
9.43. YSE 
Ethanol 15 g 
Yeast extract 3.0 g 
Soy flour 3.0 g 
K2HPO4 0.5 g 
MgSO4.7H2O 0.5 g 
NaCl 2.0 g 
CaCO3 2.0 g 
Distilled water up to 1000 ml and autoclave. 
 
9.44. F1 medium 
Bactopeptone 10 g 
Yeast extract 10 g 
Glucose 30 g 
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 Distilled water up to 1000 ml and autoclave. 
 
9.45. F2 medium 
Glycerol 10 g 
Sodium glutamate 10 g 
Yeast extract 30 g 
Distilled water up to 1000 ml and autoclave. 
 
9.46. Luria Broth (LB) 
Yeast extract 5.0 g 
Tryptone 20 g 
NaCl 5 g 
Distilled water up to 1000 ml and autoclave. To solid media add 15 g/l agar. 
 
9.47. R2A 
Yeast extract 0.5 g 
Peptone 0.5 g 
Casamino acids 0.5 g 
Glucose 0.5 g 
Starch 0.5 g 
K2HPO4 0.5 
MgSO4.7H2O 0.05 g 
Sodium pyruvate 0.3 g 
Distilled water up to 1000 ml and autoclave. 
 
9.48. BLPM (Bacillus laterosporus production medium) 
Glycerol 15 g 
Pharmamedia 10 g 
Dry yeast 12 g 
L-Leucine 5.0 g 
L-Histidine-HCl 2.0 g 
CaCO3 2.0 g 
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 Distilled water up to 1000 ml and autoclave. pH:7.0 
 
9.49. Vegetative medium 
Glycerol 20 g 
Pharmamedia 10 g 
Corn Steep liquor 10 g 
(NH4)2SO4 3.0 g 
CaCO3 4.0 g 
ZnSO4.7H2O 0.3 g 
 
9.50. TSYEM 
Trypticase soy broth 30 g 
Yeast extract 3 g 
Distilled water up to 1000 ml and autoclave. 
 
9.51. Medium 65 DSM - Gym Streptomyces medium 
Glucose  4.0 g 
Yeast extract 4.0 g 
Malt extract 10 g 
CaCO3  2.0 g 
Distilled water up to 1000 ml and autoclave. To solid media add 12 g/l agar. 
Adjust pH to 7.2 with KOH before adding agar (use pH-indicator paper). Delete CaCO3 if 
liquid medium is used. 
 
9.52. YEG 
Yeast Extract 5.0 g 
Glucose 1.0 g 
Distilled water up to 1000 ml and autoclave. 
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